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Die Zeit 
 
 
So wandelt sie, im ewig gleichen Kreise, 
Die Zeit nach ihrer alten Weise,  
Auf ihrem Wege taub und blind,  
Das unbefangene Menschenkind 
Erwartet stets vom nächsten Augenblick 
Ein unverhofftes seltsam neues Glück.  
Die Sonne geht und kehret wieder,  
Kommt Mond und sinkt die Nacht hernieder,  
Die Stunden die Wochen abwärts leiten,  
Die Wochen bringen die Jahreszeiten.  
Von außen nichts sich je erneut,  
In dir trägst du die wechselnde Zeit,  
In die nur Glück und Begebenheit 
 
Ludwig Tieck 
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Introduction 
1. Growing incidence of diabetes  
 
The burden of non-communicable diseases (NCD) is a major factor contributing to world-
wide deaths. In low- and middle-income countries, NCD count up to 80% of all annual 
deaths. Therefore, NCD have a major impact on social and economic development. At the 
individual level, NCD are associated with reduced income, increased risk of poverty and risk 
of early death (WHO, 2014). Reduced income diminishes life quality and limits the access to 
prevention and therapy. Currently, in industrialized economies, a big financial effort is 
conducted to identify and treat NCD and NCD-associated complications. A steady increase 
of prevention programs – both at the individual and policy-making level - is observed. The 
burden of NCD includes diabetes next to cancer, chronic respiratory diseases, and 
cardiovascular disease. In 2015, 415 million people were estimated to suffer from diabetes 
[2]. By 2040, a 50% increase of the world-wide diabetes (mainly type-2 diabetes (T2D)) 
incidence rate is expected. Major increases are expected in the fast-changing and fast-
growing societies of low- and middle-income countries, such as Africa, Latin America and 
South-East Asia [2]. Figure 1 summarizes the estimated number of people with diabetes 
world-wide in 2015 versus 2040.  
 
 
  
Figure 1: Number of people with diabetes worldwide and per region in 2015 and 2040 (20-79 years). 
Source: IDF atlas [2] 
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The world-wide elevated prevalence of overweight and obesity is the main risk factor for the 
development of T2D. In the modern days, adverse effects of elevated weight can already be 
found in young children (0-5 years). In 1990, 32 Mio young children were overweight and 
obese. Currently, 41 Mio and in 2025 over 70 Mio young children will have elevated weights 
[4]. These epidemiological data propose that offspring’s early metabolic health is associated 
with T2D incidence rates later in life. Causes of elevated children’s weight may be related to 
parental health before conception and maternal health during pregnancy [5, 6].   
The whole phenomenon of fast growing T2D incidence rates is described by the term 
“transgenerational diabetes” [2]. Causes contributing to transgenerational diabetes need to 
be investigated. Identification of prevention strategies may interrupt the transmission of 
adverse parental metabolic health status to new generations.  
 
2. Transition from “thrifty genes” to “fetal programming” as contributors to 
transgenerational diabetes  
 
In the 1960s James Neel published several articles describing the hypothesis of the “thrifty 
genes”. Neel explained why (sub-)populations are more prone to develop obesity and T2D in 
the modern days [7]. According to the “thrifty gene hypothesis”, evolution selected people 
with a genotype enabling them to survive periods of feast and famine. The major advantage 
of this genotype is the capacity to store fat effectively. Today, in our modern societies, this 
survival advantage has become a big disadvantage for the human population. It is 
associated with the burden of obesity [8] and T2D. Indeed, gene variants were identified in 
defined sub-populations (such as Pima Indians) [9, 10] that are the main cause for high 
prevalence of T2D, there [11]. Various common variants in genes, such as transcription 
factor 7-like 2 (TCF7L2) or fat mass and obesity-associated protein (FTO), were found 
associated with an elevated risk for T2D also in western societies [12, 13]. However, only 
modest support from population-wide genetic analysis has been found explaining the 
worldwide increase of incidence of obesity and T2D.  
Epidemiological reports of Barker and Hales [14-16] describe associations of 
maternal nutritional status and fetal risk for developing metabolic diseases. The hypothesis of 
the “thrifty phenotype” or “fetal programming” proposed by these authors describes that 
adaptation in the in-utero period contributes to the increased risk of T2D in the offspring of 
mothers with malnutrition. Ravelli et al described 1978 that men born in and after the Dutch 
hunger winter had higher rates of obesity when the period of nutritional deprivation was in 
early pregnancy and reduced rates of obesity in late fetal and early postnatal caloric 
restriction [17]. These findings gave rise to the suggestion that both, maternal over- and 
malnutrition could modify fetal risk to develop obesity and T2D later in life. 
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In parallel to these epidemiological studies, the hyperglycemia-hyperinsulinemia hypothesis 
[18] was developed by Pedersen, based on findings mainly in type-1 diabetic (T1D) women. 
He proposed that “maternal hyperglycemia results in fetal hyperglycemia and, hence, in 
hypertrophy of fetal islets tissue with insulin-hypersecretion. This again means a greater fetal 
utilization of glucose. This phenomenon will explain several abnormal structure and changes 
found in the newborn” [18]. The elevated maternal glucose levels can pass the placenta in a 
concentration-dependent manner [19] and lead to increased fetal insulin secretion upon the 
tenth week of pregnancy [20]. Fetal insulin itself is a major in-utero growth factor [21]. 
Compared to T1D, gestational diabetes (GDM) is usually associated with elevated maternal 
weight and other metabolic factors, such as elevated maternal plasma lipids [22, 23]. These 
metabolic characteristics may influence the placenta and fetal metabolism. In response to 
this discussion, the concept of “fuel-mediated teratogenesis” was established by Freinkel in 
the 1980s [24, 25]. His extension of the hyperglycemia-hyperinsulinemia hypothesis was 
supported by the finding that macrosomic offspring exists also in well controlled GDM 
pregnancies. [26]. Freinkel’s proposal is still accepted and under current investigation.  
 The “Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study”, a five-year 
prospective observational study investigated the impact of maternal health during pregnancy 
on fetal development [27]. In the HAPO study, 25,000 women in ten countries were 
monitored during pregnancy. Central laboratory measurements of maternal and fetal blood 
during and after birth, socioeconomic and maternal health history, as well as neonatal 
anthropometrics and data from 75-g oral glucose tolerance tests (OGTT) were collected. 
Early results of the HAPO study [27] and similar smaller studies indicate that both, maternal 
obesity and elevated maternal glucose levels (also below GDM diagnostic criteria) are strong 
and independent factors associated with adverse pregnancy outcome such as elevated birth 
weight, elevated amount of body fat or fetal hyperinsulinism. Both are shown to affect fetal 
risk to develop obesity and T2D later in life [28-31].  
 
3. Maternal health during pregnancy contributes to fetal health 
 
The observational findings of the HAPO study led to further studies trying to understand 
pathomechanisms induced by maternal obesity and GDM. In order to understand the 
relevance of adverse maternal health for fetal health, the physiology of normoglycaemic 
pregnancies and the role of the placenta will be explained, first.  
Physiological regulation of metabolism in normoglycaemic pregnancies 
The first two trimesters of pregnancy are characterized by an increase of maternal adipose 
tissue mass due to elevated caloric intake [32]. Additionally, insulin resistance (IR) develops 
during pregnancy. Pregnancy hormones (lactogen, estrogen, progesterone, cortisol) [33-35] 
and circulating factors known to be elevated during pregnancy, such as adiponectin, tumor 
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necrosis factor (TNF-α), leptin, and high-sensitivity C-reactive protein (hsCRP), are 
discussed to be relevant for the development of IR in all pregnancies (not only pregnancies 
accompanied by GDM) [36, 37]. The pancreas function can compensate the growing 
demand of insulin by (potentially lactogen-induced) adaptive β-cell mass expansion and 
increase of insulin secretion [38, 39]. In the third trimester, elevated IR and increasing fetal 
fuel demand lead to loss of maternal adipose tissue mass. This is associated with an 
increase in maternal plasma very-low-density lipoproteins (VLDL) and free non-esterified 
fatty acids (NEFA) [40] leading to a further reduction of insulin sensitivity in late pregnancy 
[34]. The uptake of maternal lipids by the placenta and finally the transport to the fetal 
circulation are well controlled [3, 19]. Maternal lipoproteins are degraded extracellularly 
(endothelial lipase (LIPG) and lipoprotein lipase (LPL)). NEFA are taken up by fatty acid 
transport proteins (SLC27A1 and SLC27A4), fatty acid translocase (FAT) as well as the 
plasma membrane fatty acid binding protein (p-FABP) [41]. Within the syncytiotrophoblast, 
NEFA are bound to FABP3 [42] and enter metabolic paths such as beta-oxidation or have 
their relevance in fatty acid signaling. They may also be reesterified to phospholipids (PL) 
and triglycerides (TG) which are stored within perilipin 2 (PLIN2)-positive lipid droplets in the 
syncytiotrophoblast [43]. To supply the growing fetus with fatty acids, the syncytiotrophoblast 
can release NEFA to the fetal circulation. Bound to transport proteins (α2-Heremans-Schmid 
glycoprotein alias fetuin A), they are taken up from the fetal circulation by the fetal liver where 
they are metabolized or esterified for further transport to fetal tissues [44].  
Structure and function of the placenta  
The placenta is an organ being in contact with the maternal and the fetal blood circulation. 
Via the placenta, circulating nutrients and oxygen of the maternal blood are delivered to the 
fetus, and fetal and placental products are dispensed to the mother. Additionally, the 
placenta is an endocrine organ regulating pregnancy and fetal development [45]. Placental 
adaptations in response to maternal metabolism may therefore influence fetal metabolism 
and contribute to in-utero programming.  
Placental villi consist of three layers of components, as indicated in Figure 2. The outmost 
continuous layer consists of trophoblasts (undifferentiated cytotrophoblasts and differentiated 
syncytiotrophoblasts). These cells are in direct contact with maternal blood. Within the villous 
core are mesenchymal cells, fibroblasts and macrophages (Hofbauer cells). Finally, there are 
fetal endothelial cells which collect oxygen and nutrients and release them to the fetal 
venous cord blood [45].  
The trophoblasts are the unique cell type of the placenta and therefore key components for 
maternal-fetal communication. They are the structural and biochemical barrier between 
mother and fetus [3, 45]. Moreover, they can store nutrients and are an endocrine source of 
placental hormones (i.e. estrogen, progesterone, human chorionic gonadotropin (hCG)).  
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Influence of maternal weight on fetal health  
Epigenetic programming and metabolic adaptions to the environment of germ cell [46, 47], 
the placenta, and the developing fetus [48] are discussed to modify offspring’s lifelong health 
[28]. During adaptive periods the environment can make imprints on the metabolism of a 
single individual [49].  
Maternal overweight and obesity were shown to modify placental lipid metabolism 
and storage [50]. These modifications have central relevance for metabolic programming of 
the fetus in the in-utero period [51]. According to a German National Consumption Survey 
(Nationale Verzehrsstudie ll) [52], 21% of women between 30-39 years of age are overweight 
and 14% of the women are obese in Germany. In Mexico, an exemplary transition country, 
65% of the women are overweight and 32% are obese [4]. Maternal obesity in early 
pregnancy was shown to double the risk of obesity in early childhood [53]. Furthermore, it 
was shown that maternal pre-pregnancy body-mass-index (BMI) can predict in young adults 
adiposity [54] and T2D [28].  
Influence of maternal GDM on fetal health  
Another independent factor for increased risk of the offspring to develop T2D is maternal 
GDM [29]. Following the diagnostic recommendation of the International Association of 
Diabetes and Pregnancy Study Groups (IADPSG) [55], GDM is defined as “any degree of 
glucose intolerance with onset or first recognition during pregnancy”. Clinical diagnosis 
criteria of GDM based on a 75-g OGTT are the following: fasting glucose level: 92mg/dl 
(5.11mol/l), 1-h plasma glucose: 180mg/dl (10.0mol/l), 2-h plasma glucose: 153mg/dl 
(8.5mol/l). For the diagnosis of GDM, one or more of these values must be equaled or 
exceeded. On the base of these diagnostic criteria, 13% of all live birth pregnancies were 
accompanied by GDM in 2015 in Germany [56]. In contrast, in the more overweight and 
obese population of Mexico, the prevalence was around 30% in 2012 [57]. Literature 
proposes that adverse GDM-associated effects on fetal future health are more severe 
compared to BMI effects. Epidemiological data of small GDM follow-up cohorts show that 
Figure 2: Functional layers 
of the placenta and proteins 
being involved in nutrient 
transport across the 
placenta.  
For transfer of lipids, extracellular 
lipases release fatty acids from 
maternal lipoproteins and 
intracellular binding proteins 
(FABPs) guide the fatty acids 
within the cytosol of the 
syncytiotrophoblast. Source: 
Image adopted from [3] 
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offspring of diet-treated GDM-women have an odds-ratio of 7.76 to develop T2D later in life. 
This is reflected by a T2D incidence rate of 21% till the age of 22 years [5, 58]. 
Currently, the pathophysiology of GDM is not understood. However, GDM is clinically 
characterized by elevated glucose, insulin and plasma NEFA values as well as a degree of 
IR that is no longer compensated for by insulin hypersecretion.  
Impact of GDM-associated metabolic derangement on fetal future 
health  
Metabolic derangement contributes to both, the progression of maternal IR and elevated fetal 
risk for obesity and T2D:   
- Increased plasma NEFA arising from insulin-resistant hypertrophic adipose tissue 
were shown to associate with lipoinflammation and the development of peripheral 
(skeletal muscle cells [59], hepatocytes [60], adipocytes [61], and pancreatic islets 
[62, 63]) and central [64, 65] IR. Additionally, maternal lipids are a candidate to 
explain fetal macrosomia independently of maternal glucose levels in GDM [26, 66]. 
They were proposed to affect placental and fetal lipid metabolism [25, 67] and 
mediate in utero the offspring’s risk the develop T2D later in life [26, 66].  
- Increased maternal glucose levels, also resulting from maternal IR, can pass the 
placenta in a concentration-dependent manner [29, 68]. In T1D, elevated fetal 
glucose concentrations lead to fetal hyperinsulinemia [69, 70]. For the lower glucose 
concentrations in GDM, this remains to be shown. Finally, elevated fetal insulin levels 
may have an impact on the development of IR in utero [71-73].  
The metabolic derangement in GDM may result from elevated maternal weight or weight gain 
during pregnancy. However, this is not the only cause for development of GDM, as not all 
GDM women have an elevated BMI or weight gain during pregnancy [66]. The pathogenesis 
is discussed to be accompanied by reduced pancreatic adaptation to increased insulin 
demand [74] and elevation of various placental hormones [35]. For instance, placental 
lactogen contributes to β-cell mass adaptation during pregnancy [39], lipolysis of adipose 
tissue [75] and was shown to cause peripheral IR [76]. Apelin (APL), another hormone being 
also released by the placenta is discussed to have a regulatory function in energy 
metabolism. In more details, this hormone was shown to enhance glucose uptake [77], 
lipolysis and fatty acid oxidation [78], peripherally. Additionally, central actions of APL were 
proposed to contribute in the development of T2D (i.e. by acting on hypothalamus) [79-81]. 
GDM-associated expression changes of this placental hormone could therefore contribute to 
the progression of GDM and adverse fetal programming. In pregnant women [82] elevated 
plasma APL levels were found. In pregnancy, placental APL release was proposed to 
contribute to elevated maternal APL plasma levels [82]. Its role in fetal development and 
programming is currently under investigation. Recently, it was shown that maternal 
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overnutrition elevates and maternal undernutrition reduces maternal and fetal plasma APL 
levels [83, 84]. Furthermore, maternal GDM was shown to be associated with elevated APL 
plasma levels compared to NGT women [85]. Additionally to systemic effects, placental APL 
release may enhance placental vascular functions and angiogenesis by activation of the 
apelin receptor (APJ) [82, 86].   
Impact of GDM-associated epigenetic changes on fetal future health 
Furthermore, GDM was shown to influence deoxyribonucleic acid (DNA) methylation patterns 
of the placenta and fetus [87-89]. In details, results of the Dutch hunger winter study in adults 
[90] and recent studies on epigenetic influences of GDM [91] in young children indicate that 
DNA methylation differences in blood cells can be observed in response to maternal 
nutritional and health status during pregnancy. The findings in adults indicate that epigenetic 
fetal programming may have effects on the whole lifetime of an individual. Additionally to 
DNA methylation differences, differential expression of microRNA (miRNA) in response to 
GDM-associated conditions [92-95] could contribute to epigenetic fetal programming [96].  
In general, expression of cell-type-specific genes is regulated epigenetically. Therefore, 
findings in easily accessible cells (i.e. blood cells) may not necessarily reflect epigenetic 
differences present in tissues relevant for disease progression [97]. However, our study [98] 
of Insulin Like Growth Factor Binding Protein 2 (IGFBP2) DNA methylation (a protein 
involved in the regulation of insulin sensitivity [99]) indicated that certain epigenetic 
alterations can be similar in different cell types under similar metabolic conditions (such 
stable alterations are known as metastable epigenetic marks). As shown in Figure 3, DNA 
methylation of the IGFBP2 gene was significantly elevated in murine liver of New Zealand 
obese (NZO) mice and in whole blood cells (WBC) of men with impaired glucose tolerance 
(IGT).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Comparison of IGFBP2 DNA methylation in murine liver and human whole blood cells. A: DNA 
methylation of CpG 2605 in murine liver of C57BL/6J and NZO mice. Both strains are prone to develop severe obesity, but only 
NZO mice are highly susceptible to diabetes. All data represented as mean ± SEM of N=21animals per group, respectively. B: 
DNA methylation of CpG2965 in whole blood cells from human subjects classified into normal glucose tolerant with BMI<27 
(NGT.BMI<27) or BMI>30 (NGT.BMI>30) or impaired glucose tolerant with BMI<27 (IGT.BMI<27) or BMI>30 (IGT.BMI>30). 
***p<0.001 compared with untreated control group [98].  
A B 
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Based on these marks, epigenetic differences in easily accessible compartments, such as 
whole blood, have the potential to reflect epigenetic differences in maternal and fetal tissues 
relevant for GDM progression or fetal programming [95, 97].  
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Scientific goal 
Elevated maternal pre-pregnancy BMI was shown to associate with elevated placental lipid 
content, expression of enzymes and transporters involved in lipid metabolism. Moreover, 
elevated expression and activity of inflammatory pathways were seen in the placenta of 
overweight and obese women [100]. According to results of long-term follow up studies, BMI 
and GDM are independent contributors to adverse fetal programming [68]. The 
epidemiological findings propose that GDM has stronger adverse influences on the 
offspring’s programming [5, 6]. Recent findings indicate that maternal GDM, but not maternal 
BMI, is associated with in-utero development of fetal IR [30, 71, 101]. However, the 
underlying mechanisms are currently not understood.  
Therefore, one goal of this work was to investigate effects of GDM, independently of 
BMI, on maternal plasma and placental lipid profiles. Furthermore, the effects of prominent 
GDM-associated lipid species on placental gene expression were investigated. Of special 
interest were genes involved in lipoinflammation, as earlier studies showed NEFA-mediated 
inflammatory response to be relevant for development of IR. Of further interest were 
placental hormones such as APL which was shown to be relevant in metabolic regulation. 
Hence, primary trophoblasts of normal glucose tolerant (NGT) and GDM women were 
stimulated with NEFA and expression changes of inflammatory genes, APL, and APJ, the 
APL receptor, were quantified. Biological relevance of the observed placental differences in 
inflammatory gene expression was investigated by comparison of placental macrophage 
contents in GDM and NGT women. Finally, to associate placental findings with fetal 
metabolism and the in-utero development of IR, cord blood lipid profiles, inflammatory 
patterns and APL concentrations were compared in offsprings of NGT and GDM women.  
A further goal of this work was to investigate how GDM contributes to epigenetic 
differences [46, 98, 102]. Therefore, whole-blood miRNA (WBC, lymphocyte and plasma 
miRNA) expression was compared between NGT and GDM women. In order to characterize 
which GDM-associated metabolic stimuli could be relevant for blood cell miRNA expression 
differences, primary lymphocytes of NGT and GDM were stimulated with insulin and glucose. 
Finally, the relevance of in-vitro findings was tested by correlating maternal insulin levels with 
WBC miRNA expression patterns.  
 
In conclusion, the overall scientific goal of this work was to investigate the BMI-
independent influence of maternal GDM on placental lipoinflammation and whole blood 
miRNA pattern. Based on these goals, insights in fetal GDM-associated metabolism and the 
development of in-utero IR should be gained.  
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Results  
Project l: BMI-independent effects of maternal GDM on placental 
lipoinflammation 
The aim of this Project l was to investigate effects of GDM, independently of BMI, on 
maternal plasma and placental lipid profiles. As SFA-mediated activation of toll like receptor 
(TLR)-signaling was shown to contribute to the release of inflammatory markers [63, 103, 
104], the influence of GDM on whole placenta and trophoblast-specific lipoinflammation was 
investigated. Proinflammatory cytokines such as TNF-α and interleukin 6 (IL6) were shown to 
associate with the development of IR in obese adults, earlier [59, 105, 106]. To approximate 
how lipid-associated alterations of the placenta could contribute to in-utero development of 
fetal IR, we compared a wide range of inflammatory parameters and NEFA in cord blood 
samples of NGT and GDM offspring. 
Metabolic and anthropometric characterization of pregnant women 
Table 1 shows clinical characteristics of each group of participants. Clinical characterization 
of the pregnancy cohort was conducted by the physicians and clinical scientists of the 
Clinical Study Center of the Department of Internal Medicine, Division of Endocrinology, 
Diabetology, Angiology, Nephrology and Clinical Chemistry, University Hospital Tübingen. 
Clinical characterization of the trophoblast donors and the Programming of Enhanced 
Adiposity Risk in CHildhood – Early Screening (PEACHES) cohort was conducted by the 
collaboration partners Gernot Desoye, Medical University Graz, and Regina Ensenauer, 
Ludwig Maximillians University Munich and Heinrich Heine University Düsseldorf, 
respectively. The OGTT or glucose challenge test (GCT) conducted in pregnancy week 27±2 
(pregnancy cohort) or 22±1 (PEACHES), showed significantly increased levels of fasting, 1-h 
and 2-h glucose in the GDM women compared to the NGT group (P<0.02, all). No 
statistically significant group differences were found for maternal smoking behavior, mode of 
delivery or fetal sex (P>0.05, all). A flow chart indicating which analyses were conducted in 
which cohort is shown in supplemental Figure 1 (S.71). 
Maternal plasma lipid analysis 
In multiple linear regression analysis (confounding covariates: BMI, gestational age, fetal 
sex), total and saturated (SFA) NEFA concentrations were elevated in GDM compared to 
NGT women (P≤0.05, Figure 4A, supplemental Figure 2A (S.71). Most abundant plasma 
NEFA were palmitate (C16:0), stearate (C18:0), oleate (C18:1-n9), and linoleate (C18:2-n6, 
Figure 4B). In plasma of GDM, women higher concentrations of palmitoleate (16:1-n7), 
stearate as well as docosahexaenoate (C22:6-n3) were found (P≤0.05, Figure 4B, C). 
Furthermore, statistical trends for elevated amounts of palmitate, vaccenate (C18:1-n7), 
oleate, arachidonate (C20:4-n6), and nervonate (C24:1-n9) were present (P≤0.1). Other lipid 
fractions were not analyzed within this project. Marketa Kovařova, Department of Internal 
Medicine, Division of Endocrinology, Diabetology, Angiology, Nephrology and Clinical 
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Chemistry, University Hospital Tübingen, conducted the quantification of maternal plasma 
lipids by gas chromatography.  
 
Table 1: Anthropometric and metabolic characteristics of the participants From smaller subgroups of the 
pregnancy cohort, placental mRNA analysis, lipid profile analysis and protein quantification were conducted. From a subgroup of 
the PEACHES cohort, only 1-h glucose values of a 50-g glucose challenge test (GCT) were available (N=30). Mid-pregnancy 
was defined as gestational week 27±2 (pregnancy cohort) or 22±1 gestational weeks (PEACHES cohort). All data are given as 
absolute numbers or means ± SD. Group differences of numeric characteristics were calculated by two-tailed Student’s t-test. 
Group differences of fetal sex, smoking behavior and mode of delivery were calculated using Chi-square test. P-values ≤0.05 
were considered as statistically significant and are marked by using bold fonts. aMid-pregnancy body weight was not measured 
in n=3 participants. 
 Pregnancy cohort Trophoblast cohort PEACHES cohort 
 NGT GDM P  NGT GDM P  NGT GDM P  
N 34 29 - 7 7 - 52 52 - 
Maternal age [years] 31±5 34±4 0.3 - - - 33±4 33±4 0.6 
Pre-pregnancy body 
mass index [kg/m2] 
28.1±5.1 29.4±4.6 0.4 24.9±4.5 26.0±5.
1 
0.7 23.1±2.3 23.4±2.7 0.5 
Mid-pregnancy body 
mass index [kg/m2] 
27.0±6.0 30.6±5.6 0.4 - - - 24.9±2.6a 25.4±2.8a 0.3 
Gestational age at 
delivery [week] 
40.2±6.1 37.0±5.1 0.08 39.1±1.6 38.1±1.
7 
0.3 39.4±1.1 39.0±1.0 0.1 
Fasting glucose 
[mmol/L] 
4.4±0.3 4.8±0.5 3x10-5 4.3±0.3 5.4±0.4 0.008 4.4±0.5 5.0±0.5 3x10-5 
1-h glucose [mmol/L]  
(75g OGTT) 
7.33±1.3 10.5±1.3 6x10-14 5.2±0.8 9.0±1.9 0.002 6.9±1.5 9.4±1.8 3x10-7 
2-h glucose [mmol/L]  
(75g OGTT) 
6.12±1.1 8.42±1.0 6x10-13 5.0±0.6 7.3±1.1
8 
0.009 5.8±1.3 7.4±1.5 3x10-4 
1-h glucose [mmol/L]  
(50g GCT) 
      5.9±1.4 
(N=28) 
8.3±0.6 
(N=2) 
0.02 
Smokers before 
pregnancy [N] 
2 4 0.1 - - - 6 13 0.1 
Spontaneous delivery 
[N]  
12  4  0.1 4  3  0.6 32 33 0.8 
Female neonates [N] 6 5 0.1 3 0 0.2 26 27 0.8 
 
Placental lipid analysis  
Multiple linear regression analysis of fatty acid concentrations of five lipid classes 
(cholesterol esters (CE), diglycerides (DG), PL, NEFA, and TG) from placental homogenates 
showed that GDM women have 1.5-fold increased levels of TGs in placental tissue 
compared to NGT women with similar BMI (P=0.04, Figure 4D). In placental tissue of GDM 
compared to NGT women, main SFA C16:0 and C18:0 were higher (P=0.02 and P=0.01, 
Figure 4E, supplemental Figure 2B, S.71). Furthermore, eicosatrienoate (C20:3-n6) and 
docosahexaenoate (C22:6-n3) showed statistical trends for reduced levels in GDM 
compared to NGT placental tissue (P≤0.1, Figure 4F). Similarly, reduced amounts of C20:3-
n6 were found in the PL fraction in placental tissue of GDM women (P=0.04, supplemental 
Table 1, S.74). Furthermore, GDM-associated elevations of arachinate (C20:0, PL fraction), 
as well as of docosanoate (C22:0, DG fraction, P≤0.04, supplemental Table 1, S.74) were 
observed. Differences in CE and TG fractions were absent (P>0.05, supplemental Table 1, 
S.74). Again, quantification of placental lipids was conducted by Marketa Kovařova.  
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Figure 4: Lipid profiling (A) Sum of maternal plasma non-esterified fatty acids (NEFA) of normal glucose tolerant (NGT 
N=18, white columns) and gestational diabetes (GDM N=18, black columns) women with similar BMI. (B) Highly abundant 
(>5µmol/L) and (C) less abundant (≤5µmol/L) NEFA species of maternal plasma of NGT and GDM women. (D): Sum of 
placental triacylglycerol (TG) of NGT (N=8) and GDM (N=8) women with similar BMI. (E) Highly abundant (>5%) and (F) less 
abundant NEFA species (≤5%) of placental tissue of NGT and GDM women. Shown are means ± SEM. Multiple linear 
regression analysis (confounding covariates: BMI, gestational age, fetal sex) was conducted. Significant differences (P≤0.05) 
are marked with asterisks.    
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Gene expression of whole placental tissue  
The impact of GDM on placental mRNA expression of genes involved in lipid metabolism 
(FABP3, FABP4, FAT, LIPG, LPL, PLIN2, SLC27A1, and SLC27A4) and inflammation (IL1B, 
IL6, IL8, TNF-α, TLR2, TLR4) was assessed. After multiple linear regression analysis 
(confounding covariates: BMI, gestational age, fetal sex), increased mRNA expression of 
FABP3 (fold change (FC)=1.4; P=0.01, Figure 5A), IL1B (FC=1.6; P=0.03, Figure 5B), IL6 
(FC=2.0, P=0.02, Figure 5C), and TLR2 (FC=1.1; P=0.03, Figure 5E) was detected in 
placental tissue of GDM women. Furthermore, a statistical trend for elevated IL8 (P=0.08, 
Figure 5D) mRNA expression in tissue of GDM women was observed. No further differences 
for other genes investigated were identified (P>0.1, supplemental Figure 3, S.72) As the 
chemokine IL8 plays a major role in mediation of immune cell infiltration [107] and its GDM-
associated expression has been shown earlier [108], we included it in further analyses.  
Additionally, we correlated maternal plasma total NEFA values with placental mRNA 
expression. Significant positive correlations of maternal total plasma NEFA concentrations 
and placental IL1B, IL6, and TLR2 mRNA expression were found (P≤0.05, Figure 5F, G, I). 
For placental IL8 mRNA, the association with maternal plasma NEFA concentrations was of 
borderline significance (P=0.08, Figure 5H). Multiple linear regression analysis demonstrated 
significantly elevated protein levels of IL1B and IL6 (P=0.03, Figure 5J, K) and statistical 
trends for elevated IL8 (P=0.08, Figure 5L) and TLR2 levels (P=0.07, Figure 5M, 
supplemental Figure 4, S. 72) in placental tissue of GDM women.  
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Figure 5: Gene expression in whole placental tissue. (A-E) mRNA expression of FABP3, IL1B, IL6, IL8, PLIN2, and 
TLR2 in placental tissue of normal glucose tolerant (NGT N=19) and gestational diabetes (GDM N=11) women. (F-I) Correlation 
of maternal plasma NEFA with placental mRNA expression of IL1B, IL6, IL8, and TLR2. Regression coefficient (r) and P-value 
are shown. (J-M) Protein expression of IL1B, IL6, IL8 and TLR2 in placental tissue of NGT (N=6) and GDM (N=6) women with 
similar BMI. Individual data ± SEM are shown. Significant differences (P≤0.05) detected by multiple linear regression analysis 
(confounding covariates: BMI, gestational age, fetal sex) are indicated in bold.  
Gene expression of NEFA-stimulated primary trophoblasts derived from 
NGT and GDM women 
Based on the findings in whole placenta, mRNA expression of FABP3, IL1B, IL6, TLR2, and 
PLIN2 was quantified in primary human trophoblasts derived from GDM and NGT women 
with similar BMI. After isolation from placenta, the trophoblasts were cultured in medium for 
48h. Elevated mRNA expression for IL6 (N=12), IL8 (N=12) and TLR2 (N=10) (P≤0.04, all, 
Figure 6A-C) and a statistical trend for elevated expression of PLIN2 (N=12, P=0.08, Figure 
6D) were found in trophoblasts derived from GDM women (reduced group sizes due to 
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individual Cq values>35). FABP3 (N=8) mRNA did not differ between both groups (P=0.3, 
Figure 6E). IL1B mRNA expression signals were at the detection limit (Cq values≥35) and, 
hence, excluded from further analysis.  
As we found elevated concentrations of palmitate (C16:0) and stearate (C18:0) and 
altered mRNA expression in whole placental tissue of GDM women, we investigated possible 
lipoinflammatory effects of defined NEFA on trophoblast mRNA expression. Therefore, 
primary human trophoblasts derived from GDM women and NGT controls were stimulated 
with the SFA C16:0 and the monounsaturated NEFA oleate (C18:1 n-9), respectively, as well 
as a control condition. SFA-mediated activation of TLR-signaling was shown earlier to 
contribute to an elevated mRNA expression of cytokines or chemokines (lipoinflammation) 
[59, 109]. In contrast to that, stimulation with the unsaturated fatty acid such as oleate was 
not associated with lipoinflammation. Therefore, we choose oleate as a non-lipotoxic control 
NEFA [59, 110]. As in placental tissue and non-manipulated trophoblasts, mRNA expression 
of FABP3, IL6, IL8, PLIN2, and TLR2 was analyzed in NEFA-stimulated trophoblasts. After 
stimulation with palmitate, we found increased mRNA expression of IL6, IL8, PLIN2, and 
TLR2 (P≤0.05, Figure 6F). FABP3 mRNA expression was unchanged (P=0.9, Figure 6F). 
Differences of mRNA expression after stimulation with palmitate were also observed on 
protein level: a statistical trend for elevated IL6 concentration in cell culture supernatant was 
observed (P=0.09, Figure 6H). In contrast, stimulation with oleate resulted in no different 
mRNA and protein expression (P≤0.05, Figure 6G, protein data not shown). Quantification of 
IL1B levels in the cell culture supernatant was not possible, as concentrations were below 
the detection limit.  
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Figure 6: Gene expression of inflammatory genes and of genes involved in fatty acid binding and storage 
in trophoblasts: (A-E) IL6, IL8, TLR2, PLIN2, and FABP3 mRNA expression of primary trophoblasts (N≥8) after 48-h 
incubation with medium only. Expression is given as fold change with respect to the BSA control. P-values of a one-tailed 
Student’s t-test are indicated. mRNA expression of primary trophoblasts (N=14) after 24-h stimulation with (F) 100µM palmitate 
or (G) 100µM oleate. (H) Amount of IL6 and IL8 in supernatants of primary trophoblasts after 24-h stimulation with 100µM 
palmitate relative to corresponding BSA controls. Significant differences (P≤0.05) are indicated by asterisks show the results of 
analysis of variance (ANOVA) followed by Dunnett’s test. Mean ± SEM are shown.  
Quantification of CD68-positive cells in placental tissue of NGT and GDM 
women 
To understand whether NEFA-mediated differences in trophoblastic chemokine and cytokine 
release may have a biological consequence within the placenta we compared the number of 
placental villus macrophages in NGT vs. GDM women. In placental tissue collected from 
NGT women a weak (Figure 7A) and in placental tissue of GDM women a strong (Figure 7B) 
CD68 staining was observed. Linear regression analysis revealed a statistical trend for 
elevated numbers of CD68-positive villi within the placenta of GDM compared to NGT 
women (P=0.06, Figure 7C). 
Cord blood lipid profiles and cytokine patterns 
Inflammatory patterns and NEFA profiles of neonates from GDM and NGT women with 
similar BMI were determined to investigate if placental lipoinflammation has any 
consequences for fetal metabolism. We quantified inflammatory parameters in neonatal cord 
blood. Significantly reduced concentrations of eotaxin, fibroblast growth factor (FGF)-2, IL4, 
IL9, IL17, interferon gamma-induced protein (IP-10), macrophage inflammatory protein (MIP-
1β), and tumor necrosis factor (TNF-α) were found in cord blood samples from GDM women 
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(P≤0.05, Figure 7D) after multiple linear regression analysis. In groups with smaller sample 
sizes (concentrations outside the standard curve excluded), granulocyte-macrophage colony-
stimulating factor (GM-CSF), IL6, and IL15 levels were reduced (Figure 7D). No differences 
for other inflammatory parameters were present (data not shown, P>0.1). Furthermore, we 
could detect statistical trends for reduced levels of SFA C18:0, C20:0 and C24:0 in the NEFA 
fraction of cord blood from GDM offspring in comparison to controls (P≤0.1, Figure 7E, F and 
supplemental Figure 2, S.71). In the DG fraction significant GDM-associated elevation of 
linoleate (C18:2-n6) and C20:3-n6 and reduction of myristate (C14:0) were seen (P≤0.05, 
data not shown). In the CE, PL, as well as TG fractions no differences in fatty acid profiles 
were observed (P>0.05, data not shown). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: Biological relevance of placental lipoinflammation. Staining of placental tissue derived of (A) a normal 
glucose tolerant (NGT) and (B) a gestational diabetic (GDM) woman with antibodies against CD68 (brown). Representative 
images; bar: 50µm. (C) Percentage of CD68-positive villi in tissue of GDM women (N=3) and NGT controls (N=3) with similar 
BMI. (D) Concentrations of significantly different inflammatory parameters in cord blood samples of GDM women (N=52) and 
NGT controls (N=52) with similar BMI. Cord blood concentrations of (E) highly abundant (>10µmol/L) and (F) low abundant 
(<10µmol/L) non-esterified fatty acids (NEFA) pattern in NGT (N=11) and GDM women (N=7). Multiple linear regression 
analyses (confounding covariates: BMI, gestational age, fetal sex) were conducted. Statistically significant differences (P≤0.05) 
are marked by asterisks. 
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Project ll: BMI-independent effects of maternal GDM on placental apelinergic 
system 
 
In response to GDM-associated differences of placental lipid profiles, expression of placental 
hormones could also be changed and contribute to fetal programming.  
GDM effects on placental and trophoblast APL and APJ (APL receptor) gene 
expression have not been studied yet. Furthermore, no relevant information of potential 
GDM-associated differences of fetal APL plasma concentrations is currently available. 
Therefore, the scientific goal of Project ll was to investigate BMI-independent GDM-
associated expression differences of the placental apelinergic system and its regulation by 
GDM-associated metabolic stimuli. Finally, to see if GDM-associated placental APL 
expression differences may directly influence fetal metabolism, cord blood APL levels of NGT 
and GDM were quantified and compared.  
 
Characterization of pregnant women and placental lipid analysis are shown in Project l. 
 
Placental APJ and APL gene expression 
Applying multiple linear regression analysis, significantly elevated mRNA expression of APL 
in placental tissue of GDM women was found (P=0.006, Figure 8A). APL protein expression 
was not different (P=0.8, data not shown). In comparison to NGT women, a statistical trend 
for elevated APJ mRNA expression in placental tissue of GDM women was found (P=0.09, 
Figure 8B). Quantification of APJ protein expression revealed a significantly elevated 
expression in GDM women (P=0.03, Figure 8C and D). As placental tissue consists of 
several cell types (i.e., mesenchymal cells, fibroblasts and macrophages, and (syncytio-) 
trophoblasts), potential cellular sources of APL and APJ expression were investigated. 
Immunohistochemical staining of placental slides indicated APL- and APJ-positive staining of 
the outmost layer of placental villi (syncytiotrophoblasts, Figure 8E and F) in comparison to 
isotype control (Figure 6G).  
 
 
 
 
 
 
 
 
 
 APL APJ 
Figure 8: APL (apelin) and APJ (apelin receptor) expression in placental tissue. Relative placental (A) APL and (B) 
APJ mRNA expression of NGT (N=19) and GDM (N=11) women. (C) Normalized APJ protein expression of GDM (N=6) and BMI-
matched NGT (N=6) women. Significant (P≤0.05) changes are indicated in bold and show the results of a multiple linear regression 
model (confounding covariates: BMI, gestational age, and fetal sex) Mean ± SEM are shown. (D) Western Blot shows the protein 
expression of GAPDH and APJ in GDM and NGT women with similar BMI. Immunohistochemical staining of placental tissue slides 
against (E) APL, (F) APJ, and (G) isotype control. Positive staining is indicated in brown. Representative images; bar: 50µm. 
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Association of placental APJ expression with placental NEFA content 
As shown in Project l, GDM-associated elevations of both SFA C16:0 and C18:0 were found 
in placental tissue. To investigate if placental NEFA are associated with placental APJ mRNA 
expression, linear regression analysis was conducted. A significant positive correlation was 
found for placental palmitate content and placental APJ mRNA expression (Figure 9A, 
P=0.01). Furthermore, a statistical trend for positive correlation was found between placental 
stearate content and placental APJ mRNA expression (P=0.08, Figure 9B), only. No 
correlation of placental NEFA with placental APL mRNA expression was seen (P≥0.9, data 
not shown). 
 
 
Figure 9: Correlation of placental NEFA and placental APJ mRNA expression. Correlation of placental (A) 
palmitate (C16:0) and (B) stearate (C18:0) contents with placental APJ mRNA expression (N=30). P-value and correlation 
coefficient of linear regression (r) are shown. Significant (P≤0.05) correlations are indicated in bold.  
 
Gene expression of NEFA stimulated primary trophoblasts 
Trophoblasts were isolated from NGT and GDM women with similar BMI. APL as well as APJ 
mRNA expression was compared between both groups. We could show that primary 
trophoblasts from GDM women express elevated APJ mRNA levels (P=0.03, Figure 10A). 
APL mRNA expression could not be quantified (Cq-value>35). Next, primary trophoblasts 
isolated from NGT and GDM women were stimulated with palmitate, oleate, insulin and 
corresponding controls. Stimulation with palmitate led to a significantly elevated expression 
of APJ (P=0.002, Figure 10B). Furthermore, primary cells derived from GDM women showed 
a stronger response of APJ expression after stimulation with palmitate (P=0.03, Figure 10C). 
Stimulation with oleate led to a statistical trend for elevated APJ mRNA expression (P=0.09, 
Figure 10B). Stimulation with insulin was associated with a statistical trend for reduced APJ 
gene expression (P=0.08, Figure 10B). Additionally, we collected cell culture supernatant and 
quantified APL protein release of cultured primary trophoblasts. Trophoblasts isolated from 
GDM women released more APL compared to NGT women with similar BMI (P=0.03, Figure 
10D). Stimulation of trophoblasts with insulin, palmitate and oleate was not associated with 
differences in APL release in cell culture supernatant (P>0.3, data not shown). 
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Fetal APL cord blood concentrations 
To investigate if GDM-associated differences in the placental apelinergic system have any 
impact on fetal metabolism, APL cord blood levels were quantified. After applying multiple 
linear regression analysis, no differences in APL cord blood levels collected from offspring of 
NGT and GDM women were found (N=222, PEACHES, P=0.2). As plasma APL 
concentrations were shown to be different in women and men, we stratified the data for fetal 
sex [111]. In cord blood samples of female offspring from GDM pregnancies, we observed a 
statistical trend for elevated APL cord blood concentrations (N=102, P=0.10, Figure 11 and 
Table 2). In cord blood of male offspring, no differences were seen (N=106, P=0.4, data not 
shown).  
 
Table 2: Raw APL cord blood concentrations in male and female offspring of NGT and GDM women. Data 
are given as absolute numbers and means ± SD. 
 Male offspring Female offspring 
 NGT GDM NGT GDM 
N 53 56 54 52 
Mean [ng/ml] 1.54±1.05 1.24±0.59 1.22±0.50 1.38±0.58 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11: Adjusted cord blood apelin (APL) concentrations in female offspring of NGT and GDM women. 
Adjusted concentrations of APL in fetal cord sera of NGT (N=54) and GDM (N=52) women with similar BMI. After multiple linear 
regression analysis (confounding covariates: BMI, gestational age), no statistically significant differences were seen.  
Figure 10: Gene expression of primary trophoblasts stimulated with palmitate, oleate, and insulin. (A) Apelin 
receptor (APJ) mRNA expression of primary trophoblasts (N=8) after 24-h incubation with medium only. (B) APJ expression after 
stimulation with 100µM palmitate, or oleate, or 10nM insulin (N≤7). Expression is given as fold change with respect to the BSA 
control. (C) Comparison of APJ mRNA expression after stimulation with palmitate between trophoblasts collected form NGT and 
GDM women. (D) Concentrations of apelin (APL) in cell culture supernatant of primary trophoblasts after 24-h culture in medium. 
Significant (P≤0.05) differences are indicated in bold and show the results of a one-tailed Student’s t-test. Mean ± SEM are shown.  
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Project lll: GDM-associated alterations of maternal whole blood miRNA patterns 
 
It is hypothesized that epigenetic changes occurring in response to GDM can contribute to 
progression of GDM and adverse fetal programming Furthermore, miRNA expression 
differences in easily accessible compartments can serve as future indicators for diabetes.  
In the first part of Project lll, GDM-associated WBC non-coding RNA patterns were 
investigated. Additionally, we determined which metabolic stimuli can cause similar 
transcriptional differences in lymphocytes, in vitro. 
In the second part of Project lll, maternal GDM-associated cell-free miRNA patterns 
were characterized. As plasma miRNAs were shown to be taken up by cells and contribute to 
regulation of gene expression and metabolism there [112], GDM-associated expression 
differences can have relevance for placental [113] and fetal [114] metabolism. 
Patient characteristics  
The workflow of the study including the criteria for participant selection of the screening, the 
validation, the lymphocyte donor populations as well as the cord blood population are shown 
in Figure 12. The clinical characteristics of the pregnant NGT (N=8) and GDM (N=8) women 
of the WBC screening group are shown in Table 3. Both groups did not significantly differ in 
maternal age, BMI during pregnancy, family history of parental diabetes as well as time-point 
of blood sampling and weight gain during pregnancy (P≥0.2, Table 3). Women with GDM had 
significantly increased 1-h glucose and fasting insulin values and decreased insulin 
sensitivity index (ISI, P≤0.05). Statistical trends for differences were observed in fasted and 
2-h glucose levels of the OGTT (P≤0.1). Similar associations were found in pregnant women 
of the validation and lymphocyte donor groups (Table 3). Anthropometric characteristics of 
the children (birth size, birth weight and sex) and of the non-pregnant controls (age, BMI) are 
also given in Table 3. For the plasma miRNA study, samples of NGT (N=9) and GDM (N=9) 
women were collected. Plasma of all participants of the WBC screening cohort was included. 
Characteristics of the plasma miRNA group are shown in Table 4 and are similar to those of 
the screening group. Anthropometric and metabolic characterization of the participants was 
conducted by the physicians and clinical scientists of the Clinical Study Center of the 
Department of Internal Medicine, Division of Endocrinology, Diabetology, Angiology, 
Nephrology and Clinical Chemistry, University Hospital Tübingen. 
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Figure 12: Criteria for participant selection and work flow. Whole blood was collected from normal glucose tolerant (NGT N≤9) and gestational diabetes (GDM N≤9) pregnant women for 
genome-wide transcriptome analysis of miRNAs isolated from whole blood cells (WBC) or plasma (plasma screening group). Samples were matched based on age and body mass index (BMI) and were 
derived from the pregnancy cohort. After whole blood RNA isolation, sequencing (Illumina), library preparation and biostatistical analysis (miRlastic) was conducted. Next, for qPCR validation of miRNA 
expression of WBC, NGT (N=30) and GDM (N=30) women were selected (WBC validation group). Additionally, quantification of miRNA-340 and target mRNAs was conducted in lymphocytes collected 
from pregnant NGT and GDM women (N=38, lymphocyte donors). From this group either lymphocyte cell culture (N=8) or protein quantification was conducted (N=30). Additionally, cord blood samples 
were collected from children from NGT pregnancies (mNGT N=8) and from GDM pregnancies (mGDM N=8). Finally, cell culture and miRNA-340 quantification was conducted in lymphocytes of non-
pregnant controls (N=10). Figure adopted from [1] 
Participants of pregnancy study. Exclusion criteria: previous T1D or T2D 
Inclusion of 216 women 
Maternal blood sampling and metabolic characterisation of pregnant women 
(N=216; week of pregnancy:24-32) 
Matching based on donors´ age and BMI 
WBC screening group 
(NGT N=8; GDM N=8) 
WBC validation group 
(NGT N=30; GDM N=30) 
Cord blood group 
(mNGT N=8; mGDM N=8) 
Library preparation 
Sequencing (Illumina) 
Adaptor removal (Trim Galore) 
Mapping against h38 (STAR aligner) 
Differential expression analysis with paired samples (age and BMI) and 
adjusted for pregnancy week and maternal weight gain 
Construction of miRNA-mRNA network (miRlastic) 
Matching based on childrens 
 birth size and sex  
Lymphocyte isolation  
(N=38)  
Non-pregnant, normoglycaemic  female 
participants of the TUEF study 
Anthropometric characterisation  
(N=10) 
Blood sampling (N=10)  
Lymphocyte isolation  
(N=10) 
miRNA-340 expression analysis 
Protein quantification  
(NGT N=15; GDM N=15)  
mRNA expression 
analysis 
(NGT N=15; GDM N=15)  
Lymphoycyte cell culture 
(N=8)  
Lymphocyte cell culture (N=10)  
cDNA synthesis and q-PCR (Qiagen) 
Anthropometric characterisation of pregnant women 
(N=216, week of pregnancy: 24-32)  
Fetal cord blood sampling 
Characterisation of children 
at birth 
Plasma screening group 
(NGT N=9; GDM N=9) 
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Table 3: Anthropometric and metabolic characteristics of different participant groups. All data are given as absolute numbers or means ± SD. Significant differences calculated with a 
two-tailed Student’s t-test or Chi-square-test (family history of diabetes) are marked by using bold fonts. Missing values are indicated with a minus. Blank table cells refer to not applicable data. 
 
 Screening group Validation group Cord blood group Lymphocyte donors 
Non-
pregnant 
controls 
 
NGT GDM P NGT GDM P mNGT mGDM P NGT GDM P NGT 
N 8 8 - 30 30 - 8 8 - 20 18 - 10 
Age [years] 33±5 32±3 0.7 32±4 31±4 0.4    32±4 31±4 0.3 35±8 
Body mass index 
[kg/m2] 
28.1±5.4 29.1±6.1 0.7 29.5±5.6 29.8.2±4.07 0.7    27.6±4.0 28.0±4.2 0.2 22.5±3.0 
Pregnancy week 
[weeks] 
23.0±9.5 25.9±1.7 0.4 27.6±2.37 27.0±2.3 0.4    26.5±2.0 24.8±7.2 0.3 - 
Fasting glucose 
[mmol/L] 
4.44±0.27 4.89±0.62 0.09 4.58±0.3 4.87±0.47 0.005    4.43±0.21 4.79±0.51 0.01 - 
1-h glucose [mmol/L] 7.76±1.21 10.90±0.82 0.00013 7.97±1.64 10.41±1.52 0.0001    8.17±1.08 10.79±1.01 0.0003 - 
2-h glucose [mmol/L] 6.32±1.31 7.52±1.44 0.1 6.36±1.27 7.94±1.71 0.002    6.49±1.06 7.83±1.5 0.01 - 
Fasting insulin 
[pmol/L] 
59.88±28.30 
126.38±53.7
0 
0.01 
68.71±28.1
5 
116.76±44.9
9 
0.006    
68.71±28.1
5 
116.76±45.
0 
0.006 - 
Insulin  
sensitivity index  
[1019 L2/mol2] 
13.6±6.8 5.0±2.0 0.03 9.63±4.83 5.46±2.25 0.00005    5.54±2.02 7.92±6.43 0.1 - 
Maternal weight gain 
[kg] 
6.53±3.38 11.27±9.64 0.2 6.91±3.53 8.52±6.39 0.9    7.37±5.64 7.39±9.64 0.4  
Family history of  
parental diabetes 
Paternal = 0 
Maternal = 0 
Paternal = 1 
Maternal = 0 
0.5 
Paternal = 0 
Maternal= 0 
Paternal = 4 
Maternal = 1 
0.3    
Paternal = 0 
Maternal= 0 
Paternal = 2 
Maternal =1 
0.8  
Birth weight [kg]       3.38±0.59 3.36±0.51 0.9     
Birth size [cm]       51.2±1.6 51.0±2. 6 0.8     
Fetal sex [female]       4 4 -     
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Table 4: Anthropometric characteristics of plasma miRNA screening group. All data are given as absolute 
numbers or means ± SD. Group differences were calculated by two-tailed Student’s t-test. 
  NGT GDM  P 
N 9 9 - 
Age [year] 34.44±3.80 34.44±4.31 1 
BMI [kg/m2] 28.70±5.70 27.82±4.26 0.2 
Pregnancy week of blood collection [week] 26.56±2.30 26.0 ±1.60 0.6 
Mid-pregnancy weight gain [kg] 6.57±2.79 7.13±4.05 0.8 
 
miRNA expression patterns in WBC related to maternal GDM  
To identify differential coding and non-coding RNA expression in WBC between GDM and 
NGT women with similar BMI, RNA sequencing was conducted in the WBC screening group. 
Special focus was on the comparison of the expression of miRNAs, as approximately 80% of 
the identified unique mappings among the non-coding RNA species were miRNAs (data not 
shown). The participants were selected based on maternal age and BMI. Next, data was 
adjusted for maternal weight gain and gestational age. Twenty-nine miRNAs were found to 
be elevated in WBC of GDM women (P<0.05; false discovery rate [FDR]<0.1, Table 5). No 
GDM-related reduction in miRNA expression was detected. PIWI-interacting RNAs (piRNA) 
and transfer RNA (tRNA) expression was not different between both groups. Non-coding 
RNA sequencing was conducted by Peter Huypens, Institute of Experimental Genetics, 
Helmholtz Center Munich. Bioinformatic analysis was conducted by Steffen Sass, Institute of 
Computational Biology, Helmholtz Center Munich. 
Next, miRNA sequencing results were validated by quantitative polymerase chain 
reaction (qPCR) validation experiments in a lager WBC validation group (NGT N=30, GDM 
N=30). We selected five miRNAs (miRNA-19a, -142, -143, -340, and let-7g) with the highest 
FC and with interaction sites within mRNAs negatively associated with GDM in the screening 
population. Additionally, miRNA-19b was included in qPCR validation, due to its proposed 
relevance in the network analysis (Figure 14). The six miRNAs selected for qPCR validation 
are marked in Table 5 by bold fonts. After q-PCR validation, miRNA-19a, and -19b were not 
significant differently expressed in WBC between GDM and NGT (P≥0.3, both, Figure 13A, 
B). For miRNA-142, miRNA-143, and let-7g, statistical trends for elevated expression in 
GDM women were observed (0.06≤P≤0.1, Figure 13 C-E). Out of six miRNAs selected for 
validation, miRNA-340 was the only one found to be significantly elevated in GDM (P=0.03, 
Figure 13F).   
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Table 5: MiRNAs positively associated with maternal GDM in whole blood cells of the screening group. 
Table 5 shows miRNAs significantly (P<0.05; false discovery rate (FDR)<0.1) associated with GDM in the screening group. The 
samples were paired based on maternal age and BMI and adjusted for maternal weight gain and pregnancy week. GDM/NGT 
was defined as endpoint variable. miRNAs are sorted by fold changes (FCs), shown in the 2nd column. Logarithmically 
transformed counts per million (logCPM), indicating the relative abundance of the transcript are shown in the 3rd column of the 
table. P-values and FDR are indicated in the 4th and 5th column, respectively. MiRNAs shown in bold fonts indicate those which 
were selected for qPCR validation experiments. 
Name FC logCPM P FDR 
miRNA-199a-3p 2.213 3.917 7.50E-03 0.083 
miRNA-199b-3p 2.213 3.917 7.50E-03 0.083 
miRNA-15a-5p 2.169 9.190 4.88E-03 0.072 
miRNA-19a-3p 2.154 5.782 1.48E-03 0.035 
miRNA-96-5p 2.036 7.029 1.65E-04 0.020 
let-7g-5p 1.965 12.247 4.32E-04 0.024 
miRNA-143-3p 1.946 7.242 8.72E-04 0.028 
miRNA-340-5p 1.907 6.828 7.06E-04 0.028 
miRNA-142-5p 1.882 11.583 3.36E-04 0.024 
miRNA-1307-5p 1.870 5.413 1.04E-03 0.028 
let-7f-5p 1.836 11.930 5.32E-03 0.072 
miRNA-107 1.825 9.919 6.44E-04 0.028 
let-7c-5p 1.749 4.566 1.81E-04 0.020 
miRNA-18a-5p 1.735 4.410 8.56E-03 0.088 
miRNA-660-5p 1.730 6.842 2.15E-03 0.041 
miRNA-17-3p 1.728 5.856 2.15E-04 0.020 
miRNA-19b-3p 1.629 9.256 5.28E-03 0.072 
miRNA-106b-5p 1.617 8.228 5.65E-03 0.073 
let-7a-5p 1.611 12.127 1.10E-03 0.028 
miRNA-451a 1.606 17.754 3.96E-03 0.067 
let-7e-5p 1.589 3.544 8.35E-03 0.088 
let-7i-5p 1.589 11.408 6.85E-03 0.082 
miRNA-148a-3p 1.584 11.695 4.21E-03 0.067 
miRNA-22-3p 1.577 13.539 9.01E-04 0.028 
miRNA-17-5p 1.571 9.101 9.47E-03 0.094 
miRNA-145-5p 1.569 4.349 6.23E-03 0.078 
miRNA-93-5p 1.546 10.233 3.88E-03 0.067 
miRNA-103a-3p 1.495 12.179 1.75E-03 0.035 
miRNA-103b 1.495 12.179 1.75E-03 0.035 
 
mRNA expression patterns in WBC related to maternal GDM 
Similarly, mRNA sequencing was conducted within the WBC screening population (Peter 
Huypens) and the dataset was examined (Steffen Sass). One hundred sixty-three mRNAs 
were significantly (P<0.05; FDR<0.1) reduced in GDM in the WBC screening group (P<0.05; 
FDR<0.1, supplemental Table 2, S.74). No GDM-related elevation of mRNA was detected. 
For mRNA qPCR validation, predicted targets of miRNA-340, shown to be negatively related 
with GDM (P<0.05; FDR<0.2), were selected. Different group sizes of the validation groups 
result from limited sample amount (N=60 for CRY2, GRB10, PAIP1; N=48 for ID2, PITPNB, 
SCARB2, and SPRY3). GDM-related significant reductions in expression were observed for 
GBR10 (P=0.05, Figure 13H) and PAIP1 (P=0.007, Figure 13M). For CRY2, ID2, PITPNB, 
SCARB2, and SPRY3 no expression differences related to GDM were found (Figure 13 G, I, 
J-L).  
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A 
G 
Figure 13: Validation of miRNA and mRNA sequencing results within the validation group by qPCR. 
Sequencing results were validated within the validation group of normal glucose tolerant (NGT N=30) and gestational 
diabetes (GDM N=30) pregnant women by qPCR. (A-F) Six miRNAs were selected for qPCR validation experiments 
within the validation. (G-M) Seven mRNAs, which are all predicted targets of miRNA-340 were selected for qPCR 
validation experiments. Samples were paired based on maternal age and body mass index. Data was adjusted for 
pregnancy week and weight gain till the end of second trimester. Shown are the means ± SD. Differences considered as 
statistically significant (P≤0.05) are marked by bold fonts. Figure adopted from [1] 
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Results of the WBC screening and WBC validation experiments are displayed in the network 
analysis generated with miRlastic R by Steffen Sass. Figure 14 shows each GDM-related 
miRNA in the center of the cluster, surrounded by their mRNA targets negatively related with 
GDM within our dataset (P<0.05, FDR<0.1). 
miRNA-340 and GRB10 and PAIP1 mRNA and protein expression in 
lymphocytes of NGT and GDM women 
Primary lymphocytes were collected from participants (NGT N=15, GDM N=15) in order to 
see if GDM-related miRNA and mRNA expression is similar to the GDM-related expression in 
WBC. Expression analysis of miRNA-340 and both predicted targets GRB10 and PAIP1 
were conducted. In lymphocytes of GDM women, significantly elevated miRNA-340 
expression was seen (P=0.02, Figure 15A). Furthermore, a statistical trend for reduced 
GRB10 mRNA expression was observed in lymphocytes of GDM women (P=0.1, Figure 
15B). Differences for PAIP1 mRNA expression between both groups were absent (P=0.3, 
Figure 15C). As miRNAs can influence target gene expression via mRNA degradation and 
inhibition of protein translation, expression of GRB10 and PAIP1 was quantified on protein 
level, additionally [115]. Relative protein quantification by Western blots indicate, that GRB10 
protein expression was not different between both groups (P=0.7, supplemental Figure 5A, 
B, S.73). For PAIP1 a statistical trend for reduced protein expression was observed after 
normalization with the reference protein GAPDH (P=0.06, supplemental Figure 5A, C, S.73). 
To investigate if miRNA-340 expression has any association with PAIP1 mRNA or protein 
expression, a regression analyses conducted. We found no significant correlation between 
miRNA-340 and PAIP1 mRNA expression (N=30; P=0.3, Figure 15D). However, a significant 
negative correlation of miRNA-340 with PAIP1 protein expression (N=30; P=0.006, Figure 
15E) was observed. Batch correction was included in the analysis, as RNA isolation of 
lymphocytes was conducted in two independent experiments.  
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Figure 14: miRNA-mRNA regulatory network inference. MiRNAs 
positively related with GDM are indicated as red dots (P<0.05; FDR<0.1). 
They are connected with blue dots, indicating predicted target mRNAs. Blue 
dots with an orange frame showed a significant (P<0.05; FDR<0.2) down-
regulation related with GDM. MiRNA-340, GRB10, and PAIP1 as validated 
components are marked in yellow. For data analysis the R package 
miRlastic was used. Figure adopted from [1] 
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Assessment of miRNA-340 in WBC from cord blood samples 
As currently no indicator for GDM-associated fetal programming is available, we tested 
whether miRNA expression differences seen in WBC of GDM women during pregnancy are 
reflected in their offspring. Cord blood of children born from NGT (mNGT N=8) and GDM 
(mGDM N=8) pregnancies was collected. Quantification of miRNA-340 followed by a paired 
analysis (paired based on fetal sex and birth size) no significant association of miRNA-340 
expression with maternal GDM was observed (P=0.2, supplemental Figure 6, S. 73). 
Anthropometric data of the children is shown in Table 3, S.32).  
Regulation of miRNA-340 and its target mRNAs by glucose and insulin in 
human lymphocytes 
To identify which GDM-associated metabolic stimuli may contribute to the elevated miRNA-
340 in WBC and lymphocytes from GDM women, primary cell culture was conducted. 
Primary lymphocytes of pregnant women (N=8) were cultured in medium containing 5.5mM 
or 25.5mM glucose. These two glucose concentrations reflect fasting and postprandial 
glucose levels, respectively. Increased glucose levels were related with significantly reduced 
levels of miRNA-340 (P<0.05, Figure 16A). Furthermore, influences of elevated insulin 
concentrations on lymphocyte miRNA-340 expression were investigated. Cells were cultured 
in medium containing either 100nM insulin and 5.5mM glucose or 10nM insulin and 25.5mM 
glucose. The first condition should mimic increased fasting insulinemia and IR, the second 
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Figure 15: Expression of miRNA-340, GRB10 and PAIP1 in lymphocytes. RNA from lymphocytes of fifteen NGT 
(N=15) and GDM (N=15) women each was collected. Samples were paired based on maternal age and body mass index. 
Expression of (A) miRNA-340 and both targets (B) GRB10 and (C) PAIP1 was compared.miRNA-340 expression was 
correlated with PAIP1 (D) mRNA and (E) protein expression in lymphocytes. Shown are means ± SD. Statistically significant P-
values (P≤0.05) are marked by bold fonts. Figure adopted from [1]  
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condition impaired insulin secretion in a severely diabetic pregnant woman. Again, clinical 
characteristics of the women donating the lymphocytes are shown in the Table 3, S.32). 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
  
 
 
Figure 16: Expression of miRNA-340 in lymphocytes and whole blood cells in response to glucose and 
insulin. miRNA expression in non-cultured and cultured lymphocytes of pregnant women was investigated (N=8). (A) 
Comparison of non-cultured (no treatment, non-colored bars) and lymphocytes cultured with 5.5mM (blue bars) or 25.5mM 
(violet bars) glucose. (B) Comparison of cells cultured in medium containing 5.5mM glucose without and with 100nM insulin 
(light blue bars), respectively, and cells cultured in medium containing 25.5mM glucose without and with 10nM insulin (light 
violet bars), respectively. miRNA expression in whole blood cells (WBC) in relation to fasting (C) insulin and (D) glucose levels 
within the validation cohort (N=30). Shown are means ± SD. Statistically significant P-values (P≤0.05) are marked by bold fonts. 
Figure adopted from [1] 
An increased miRNA-340 expression was observed after stimulation of cells with 5.5mM 
glucose and 100nM insulin in comparison to cells stimulated with 5.5mM only (P=0.03; 
Figure 16B). Additionally, stimulation of cells with conditions mimicking impaired insulin 
secretion (higher glucose (25.5mM) and lower insulin (10nM)) was associated with a 
statistical trend for insulin-dependently elevated miRNA-340 expression (P=0.07, Figure 
16B). No differential miRNA expression of lymphocytes collected from NGT and GDM 
women was seen by MANOVA (P≥0.05) (data not shown).  
To investigate if the in-vitro effects of insulin and glucose are reflected in vivo, a linear 
regression analysis of maternal fasting insulin and glucose levels with WBC miRNA-340 
expression was conducted. Maternal fasting insulin levels were positively associated with 
WBC miRNA-340 expression (P=0.01, Figure 16C). No significant association was present 
between miRNA-340 and fasting glucose (P=0.2, Figure 16D).  
Lymphocytes of non-pregnant women being stimulated with identical metabolic stimuli did 
not show similar differences found in lymphocytes of pregnant women. Only stimulation with 
P=0.2 
A 
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10nM insulin at high glucose levels was associated with an increased expression of miRNA-
340 when compared to stimulation with high glucose only (P=0.05, Figure 17A and 17B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17: Expression of miRNA-340 in lymphocytes of non-pregnant women stimulated with glucose and 
insulin. miRNA expression in non-cultured and cultured lymphocytes of non-pregnant women was investigated (N=10). (A) 
Comparison of non-cultured (no treatment, non-colored bars) and lymphocytes cultured with 5.5mM (blue bars) or 25.5mM 
(violet bars) glucose. (B) Comparison of cells cultured in medium containing 5.5mM glucose without and with 100nM insulin 
(light blue bars), respectively, and cells cultured in medium containing 25.5mM glucose without and with 10nM insulin (light 
violet bars), respectively. Shown are means ± SD. Differences considered as statistically significant (P≤0.05) are marked by 
bold fonts. Figure adopted from [1] 
miRNA and mRNA expression patterns in WBC related to maternal BMI 
Secondary outcome variable was maternal BMI, as this parameter is an important risk factor 
for the development of GDM during pregnancy [116]. For detections of any associations 
between BMI and RNA expression independently of glucose tolerance status, again a non-
paired analysis was conducted with the dataset collected from the screening group. For this 
secondary analysis the confounding covariates were: GDM, maternal age, pregnancy week, 
and maternal weight gain. We found four miRNAs to be positively associated with maternal 
BMI (P<0.05; FDR<0.1, Table 6). No overlap of this set of miRNAs with them found in GDM 
was observed. Furthermore, BMI-related differences in miRNA expression were small, as 
indicated by the low FC values. No down-regulated miRNAs were found. Additionally, no 
expression differences of piRNA and tRNA were detected. Analysis of the mRNA dataset 
within the secondary endpoint BMI revealed 25 mRNAs to be positively and 15 mRNAs to be 
negatively associated with maternal BMI (P<0.05; FDR<0.1, supplemental Table 4, S.78).   
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Table 6: MiRNAs associated with maternal BMI in whole blood cells of the screening group. Table 6 shows 
miRNAs significantly (P<0.05; false discovery rate (FDR)<0.1) associated with maternal BMI in the screening group. An 
unpaired analysis was conducted and adjusted for gestational diabetes, age, maternal weight gain, and pregnancy week. 
miRNAs are sorted by fold changes (FCs), shown in the 2nd column. Logarithmically transformed counts per million (logCPM), 
indicating the relative abundance of the transcript are shown in the 3rd column of the table. P-values and FDR are indicated in 
the 4th and 5th column, respectively.  
Name FC P FDR 
miRNA-4473 1.075 3.8E-06 0.001 
miRNA-199a-5p 1.074 1.3E-05 0.002 
miRNA-339-5p 1.068 5.8E-05 0.006 
miRNA-3653-5p 1.060 1.3E-03 0.096 
 
Plasma miRNA pattern in pregnant NGT and GDM women 
Cell-free plasma miRNAs are not only potential indicators of epigenetic differences, they are 
also proposed to have functional relevance in disease progression [112-114]. The main 
research question of the second part of Project lll was to identify GDM-associated miRNA in 
maternal plasma collected in gestational week 24-30. 
As indicated in Figure 12 (S.31), all participants included in WBC miRNA pattern analysis 
were included in plasma miRNA pattern analysis. Therefore, anthropometric and metabolic 
characteristics of the participants (GDM N=9, NGT N=9) shown in Table 4 (S. 33) are similar 
to those shown in Table 3 (screening group, S.32). miRNA isolation from maternal plasma 
was followed by genome-wide miRNA-sequencing (conducted by Peter Huypens). Following 
the recommendation of Richa Batra, Institute of Computational Biology, Helmholtz Center 
Munich, the responsible bioinformatician of this subproject, an unpaired analysis was applied 
(confounding covariates: maternal age, BMI, weight gain and gestational week at time of 
blood collection). As indicated in supplemental Table 5 (S.79), 84 miRNA were shown to be 
negatively associated with maternal GDM. Supplemental Table 6 (S. 81) shows 52 miRNAs 
positively associated with maternal GDM. Comparisons between GDM-related miRNAs of 
maternal WBC and maternal plasma, revealed let-7c-5p to be the only overlapping miRNA 
positively associated with GDM.  
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Discussion 
The increasing incidence of adiposity and T2D is discussed to be also a consequence of 
adverse fetal programming during pregnancy [6]. In-utero development of fetal IR in women 
with GDM [71-73] was proposed to be causative for the later development of T2D [117]. 
Underlying mechanisms are still unknown. An improved understanding might serve for the 
future development of prevention strategies.  
Maternal GDM is associated with metabolic alterations (elevated plasma glucose, 
insulin and NEFA concentrations) which may alter placental function and subsequently fetal 
metabolism. GDM-associated metabolic alterations may also imply epigenetic differences 
leading to adverse fetal programming [6] and elevated maternal risk to develop T2D after a 
pregnancy accompanied by GDM [48, 102]. 
 
Project l: BMI-independent effects of maternal GDM on placental 
lipoinflammation 
 
The placenta is an easily accessible mainly fetal tissue at the interface between maternal 
and fetal metabolism. It is of high relevance to gain insight into fetal metabolism [44] due to 
its metabolic and humoral control functions in pregnancy [45]. Elevated placental expression 
of genes involved in lipid metabolism [43, 118-120] and inflammation [119, 121-123] in obese 
pregnant women were proposed to be relevant for obesity-related fetal programming. To 
investigate if BMI-independent but GDM-associated differences of the placenta may 
contribute to adverse GDM-associated fetal outcome, such as IR [71, 72]; we analyzed 
maternal plasma and placental lipid profiles and their involvement on placental 
lipoinflammation and fetal metabolism (Figure 18). 
In details, we observed significant elevation of SFA in maternal plasma of GDM 
women (Figure 18,). Earlier findings in patients with T2D associated elevated plasma SFA 
with development of central and peripheral IR [64, 65, 106, 117, 124]. In pregnancies 
accompanied by GDM both maternal and fetal metabolism show elevated IR [71, 72]. 
Findings of elevated maternal plasma NEFA propose, that GDM-associated differences of 
maternal lipid metabolism could have relevance for development of elevated IR [35]. Our 
results of Project l propose that differences of maternal plasma lipid content and pattern may 
affect placental lipid metabolism: Placental lipases hydrolyze maternal lipoproteins. NEFA, 
derived from lipoproteins and from adipose tissue lipolysis, are taken up by fatty acid 
transport proteins of syncytiotrophoblasts [44]. We found elevated FABP3 mRNA expression 
in placental tissue of GDM women, proposing an elevated NEFA uptake by 
syncytiotrophoblasts (Figure 18,). Within this placenta-specific cell type, NEFA can become 
reesterified and finally stored as TG within lipid droplets. Earlier publications showed a 
positive association between maternal BMI and PLIN2 expression as well as placental TG 
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content [43]. However, BMI-independent effects of GDM on placental TG were unknown, but 
of high relevance as epidemiological effects of GDM on fetal health indicate [6, 28]. Within 
our study we could show a 50-%-elevation of total placental TG content by GDM 
independently of BMI. Corresponding to that, we could show that placental tissue and 
trophoblasts of GDM women express higher levels of the lipid droplet associated protein 
PLIN2 on mRNA expression level. Therefore, we conclude, that maternal GDM increases 
placental TG lipid storage independently of maternal BMI (Figure 18,). 
 
Figure 18: Placental lipoinflammation in women with GDM. This figure summarizes new findings of Project l. Details 
can be found in the text. Shortly, elevated saturated fatty acids (SFA) were quantified in maternal plasma and placental 
tissue. However, they are not transmitted to the fetus. GDM-associated elevated amounts of TG are presumably stored in 
PLIN2-positive lipid droplets within the syncytiotrophoblast (PLIN2 staining indicated in red; picture friendly provided by B. 
Hirschmugl) . Presumably TLR-mediated elevated inflammatory gene expression  is associated with elevated placental 
macrophage infiltration, is however also not transmitted to the fetus (CD68 staining for placental macrophages is indicated 
in brown). All genes indicated showed an elevated expression in placental tissue or primary trophoblasts of GDM women.  
Additionally to elevated total placental TG content, we could show in Project l for the first time 
that non-esterified SFA are elevated in placental tissue of GDM women (Figure 18,). SFA, 
such as palmitate or stearate, were shown to contribute to the activation of TLR signaling in 
vitro and in vivo, earlier [125]. Similar to the classical ligand lipopolysaccharide, SFA can 
bind to different members of the TLR receptor family, such as TLR2 and TLR4 [104, 125, 
126]. SFA-mediated activation of TLR receptors leads to MyD88-dependent activation of 
NFKB, initiation of transcription of inflammatory genes and finally elevated cellular release of 
cytokines (IL6, IL1B, TNF-α) and chemokines (IL8) [127]. In this study, TLR2 expression was 
 
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elevated in placental tissue of GDM women and positively associated with maternal plasma 
NEFA concentrations (Figure 18,). Other mechanisms which may contribute to placental 
SFA signaling could be free fatty acid receptor (FFAR)- [128] or peroxisome proliferator-
activated receptor (PPAR)-associated [129]. However they were not included in this study. 
Literature provides evidence that signaling via TLR, FFAR, and PPAR occurs in placental 
tissue [129, 130] and trophoblasts [100, 119, 131]. Maternal obesity was associated earlier 
with increased placental expression of inflammatory cytokines and chemokines [23, 131-
133]. Significant elevations of, i.e., IL1B (FC=1.87) mRNA expression were found in placental 
tissue of obese compared to non-obese women [133]. Within Project l, we could identify 
elevated expression of proinflammatory cytokines (IL6 and IL1B) in whole placental tissue of 
GDM women, independently of maternal BMI (Figure 18,). In comparison to obesity-
associated placental effects on inflammatory gene expression [133], GDM-associated effects 
(independently of maternal BMI) have similar effect sizes. By correlation of maternal plasma 
NEFA concentrations with placental inflammatory gene expression, we could directly link 
maternal lipid metabolism with placental lipoinflammation (IL1B, IL6).  
 Furthermore, elevated placental expression of inflammatory genes was reflected by 
elevated inflammatory gene expression and protein release of primary trophoblasts isolated 
from GDM compared to NGT women. These findings could result from in-vivo effects of fatty 
acids on gene expression that are maintained during placental preparation and subsequent 
isolation and culture of the cells. To directly associate placental SFA content with 
inflammatory gene expression involved in the development of IR, we stimulated primary 
trophoblasts with SFA. Stimulation with palmitate, but not oleate, was associated with 
elevated mRNA and a statistical trend for elevated protein expression of IL6 and IL8. This 
result supports earlier findings indicating that SFA, contribute to the activation of TLR and 
nuclear factor kappa-light-chain-enhancer of activated B cells (NFKB) [110, 126, 134]. SFA-
induced elevated levels of proinflammatory cytokines are proposed to impair insulin 
sensitivity by reducing insulin receptor signaling [135, 136].  
Additionally, SFA-mediated activation of TLR was shown to contribute to an increased 
gene expression of the chemokine IL8 and, therefore, may be a potential mediator of 
placental macrophage infiltration [137] (Figure 18,). Comparisons of villous macrophage 
content between NGT and GDM women revealed an elevated amount of CD68-positive 
macrophages in placental tissue of GDM women (Figure 18,). GDM-associated attraction 
and accumulation of placental macrophages could enhance placental lipoinflammation [123].  
Based on these results, we hypothesized that GDM-associated disturbance of 
maternal and placental lipid metabolism might be the missing link to the in-utero 
development of fetal IR present in GDM [30, 44, 71, 72]. To investigate this hypothesis, we 
focused on the potential effect of GDM-associated differences of SFA and inflammatory 
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parameters in fetal cord blood. Based on our findings in placenta of GDM women, we 
assumed to find elevated concentrations of SFA (Figure 18,) and proinflammatory 
parameters (Figure 18,) in fetal cord blood of GDM offspring. However, we could not find 
GDM-associated elevations. Major SFA species were not elevated in fetal cord blood of 
GDM offspring. Rather, a statistical trend for reduced concentration of sum of SFA was seen 
in the cord blood of GDM offspring. Additionally several cytokines were found to have a lower 
concentration in offspring of GDM women. Therefore, we conclude, that GDM-associated 
placental lipoinflammation and accumulation of SFA are not directly transmitted to the fetal 
circulation and are, therefore, unlikely to be involved with the in-utero development of 
adverse fetal outcome such as elevated risk to develop T2D later in life. Altogether, the 
findings of elevated SFA in placental tissue of GDM women, but not in the cord blood of 
GDM offspring propose a potential protective role of the placenta for the developing fetus at 
least in well controlled GDM pregnancies at the end of pregnancy. Future studies need to 
investigate if GDM-associated differences of the metabolomic profile of the placenta and the 
cord blood are present. Furthermore, epigenetic studies should be performed to investigate 
mechanisms for basal mRNA expression differences found in trophoblasts of NGT and GDM 
women.  
We acknowledge limitations of Project l (partly also valid for Project ll). We did not 
investigate epigenetic effects which are proposed to be a possible mechanism contributing to 
adverse fetal programming [138, 139]. NEFA can act as epigenetic regulators. Short fatty 
acids can inhibit histone deacetylase activity [140]. Additionally, stimulation of skeletal 
muscle cultures with palmitate led to elevated methylation of peroxisome proliferator-
activated receptor gamma coactivator 1-α (PGC-1α), a central regulator of energy 
metabolism [138]. Future studies need to be conducted to investigate the nutrient-dependent 
epigenetic regulation of genes involved in placental metabolism and fetal development. 
Furthermore, our findings may not reflect the placental lipid profile and gene expression as a 
whole, as we collected placental samples from the fetal facing surface of the placenta, only. 
Also, influences of dietary differences between NGT and GDM women on the data were not 
taken into account, as no dietary information during pregnancy was collected in the 
pregnancy study. Moreover, limited sample sizes available in defined sub-experiments are a 
further limitation of this study; however replication of findings in these subgroups supports 
robustness of the data. 
In summary, based on our findings, we could show that maternal GDM exerts BMI-
independent effects including elevation of maternal plasma and placental SFA 
concentrations as well as fatty acid-mediated lipoinflammation. However, neither 
inflammatory parameters nor SFA appear to be transmitted to the fetus. Therefore, we 
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conclude that placental lipoinflammation of GDM mothers is not directly involved in GDM-
associated adverse fetal programming.  
Project ll: BMI-independent effects of maternal GDM on placental apelinergic 
system 
 
As neither elevated amounts of SFA nor inflammatory parameters were seen in cord blood of 
newborns from GDM women, other mechanisms modifying fetal risk of IR in utero and, 
subsequently, future adiposity and T2D [6] need to be explored. Beside of classical 
pregnancy hormones [39, 75, 76], the placenta releases hormones involved in regulation of 
metabolism, such as APL. GDM-associated differences in the expression of the placental 
apelinergic system could contribute to metabolic in-utero programming with life-long 
consequences of the offspring [83, 141].  
Within this study, we could show elevated APL mRNA expression in placental tissue 
of GDM women compared to NGT controls. Furthermore, we could proof that trophoblasts 
are the cell type responsible for placental APL expression. Corresponding to elevated 
placental mRNA expression in GDM, primary trophoblasts collected from GDM women were 
shown to release higher amounts of APL in vitro. Within our study, the amount of cultured 
cells was too low for trophoblast APL mRNA or protein quantification. However, earlier 
publications propose that insulin [142, 143] as well as proinflammatory parameters [144, 145] 
and polyunsaturated NEFA [146] could stimulate APL release (i.e., in adipocytes). Therefore, 
the impact of other GDM-associated metabolic and inflammatory stimuli on trophoblast APL 
release should be investigated in future studies. Furthermore, as APL expression is 
proposed to be epigenetically regulated, studies on APL-targeting miRNAs and APL DNA 
methylation pattern [147] should be conducted.  
To investigate if GDM-associated differences in placental trophoblast APL release 
have any effect on APL cord blood concentration, fetal APL concentrations were quantified in 
female and male NGT and GDM offspring. No significant differences were observed in the 
overall cohort. However, as sex-specific differences of plasma APL levels were shown, we 
investigated GDM-associated effects in male and female offspring, separately [111]. We 
found a statistical trend for elevated fetal APL concentrations in female offspring of GDM 
women. Subtly elevated in-utero APL concentrations may in long-term shape fetal 
metabolism [77] also via targeting central pathways [79]. Future studies should focus on 
quantification of APL in well characterized larger cohorts. Fetal sex should be considered as 
important confounder in such studies [111].  
 Additionally to systemic effects, trophoblast APL release may have autocrine effects 
via targeting the trophoblast APJ receptor. Differential placental APJ expression was shown 
to have a high relevance for fetal health [83, 148, 149]. Within this study, we could show an 
elevated APJ expression in placenta and trophoblasts of GDM women. Via 
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immunohistochemical staining it became visible, that trophoblasts are the major placental cell 
type of APJ expression. Stimulation of primary trophoblasts with the SFA palmitate was 
associated with elevated APJ mRNA expression. The stimulatory effect was more 
pronounced in trophoblasts isolated from GDM women, an observation that may in parts also 
result from GDM-associated epigenetic differences. As SFA are shown to be more abundant 
in placental tissue of GDM women, the positive correlation between placental palmitate 
concentration and APJ mRNA expression underlines the in-vitro results. Further differences 
in response to stimulation were absent although earlier findings indicate that 
hyperinsulinaemia could elevate APJ expression in adipose tissue of humans [150]. 
Placental angiogenesis and sufficient placental vascularization, both co-regulated by APJ-
signaling, were shown to be essential for placental function such as transplacental nutrient 
transfer [82]. Reduced APJ signaling in preeclampsia [148] and in-utero growth restriction 
[151] was shown to have a negative impact on placental angiogenesis. In contrast to that, 
GDM was shown to be associated with elevated placental vascularization [152, 153] that 
may also result from SFA-mediated increased APJ expression. Further studies should 
investigate the underestimated role of APJ for placental development and fetal programming 
[154].  
 In summary, we could show an elevation of placental and trophoblast APL and APJ 
expression. Furthermore, palmitate was shown to increase APJ mRNA expression in human 
primary trophoblast. Currently, it is not clear whether elevated GDM-associated placental 
APL release contributes to fetal cord blood APL concentrations.  
In conclusion, we propose that GDM-associated differences of APJ expression could be of 
high relevance for placental vascularization [155] and therefore fetal development. 
Furthermore, the autocrine effects of altered GDM-associated APL release could give 
insights in adverse metabolic programming of GDM offspring [5].  
 
Project lll: GDM-associated effects on maternal whole blood miRNA patterns  
 
The biological relevance of miRNAs in the development of obesity and diabetes has been 
accepted in the last years [92-94]. Several studies have been conducted to associate miRNA 
expression patterns with the development, progression, and prevention of diabetes. 
Additionally to circulating plasma miRNAs [95, 156], transcriptomic differences in easily 
accessible blood cells are of growing relevance [97]. We conducted this study to see if 
alterations in miRNA-dependent programming related to GDM can be detected in maternal 
whole blood.  
Sequencing of miRNA isolated from WBC of NGT and GDM women during pregnancy 
revealed an elevated expression of 29 miRNAs in WBC of GDM women. To investigate the 
relevance of these sequencing results, we conducted qPCR validation experiments in a 
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larger validation group. In this experiment, out of six selected miRNAs, miRNA-340 was the 
only miRNA which we could validate to be elevated in lymphocytes of GDM women. 
Additionally, quantification of miRNA-340 expression was conducted in isolated lymphocytes. 
Again, significantly elevated miRNA-340 expression was found in cells collected from GDM 
women. miRNA-340 is a miRNA newly described in the context of GDM or diabetes in 
general. Only one earlier study described elevated circulating levels of miRNA-340 in newly 
diagnosed T1D children [157]. For three more miRNA (miRNA-142, miRNA-143, miRNA-let-
7g), which showed a statistical trend for elevated expression in WBC of GDM women, more 
literature findings are present: elevated circulating concentrations of miRNA-142 were seen 
in obese and non-obese T2D patient [158]. Additionally, metformin therapy reduced 
circulating concentrations of miRNA-142 in these patients. miRNA-143 was shown to have 
an increases expression in rat peripheral mononuclear blood cells [159]. Moreover, in liver of 
diabetic mouse model, increased miRNA-143 expression was detected. Additionally, miRNA-
143 overexpression was associated with impaired insulin sensitivity and glucose 
homeostasis [160]. In our WBC screening group, seven members of the miRNA-let-7 family 
were positively related with GDM in WBC in miRNA sequencing. The miRNA-let-7 family is 
shown to regulate peripheral glucose metabolism [161]. Additionally, whole-body transgenic 
mice overexpressing let-7a, -7d, or 7f were shown to be glucose-intolerant [162]. Similarly to 
our finding, diabetes or diabetes-associated metabolic stimuli were associated with increased 
expression of members of the miRNA-let-7 family, in vivo and in vitro [163, 164] .  
To understand if elevated miRNA-340 expression levels have any biological 
relevance, the expression of target genes was analyzed. For PAIP1, significant GDM-related 
reduction in mRNA expression could be found in maternal WBC. Additionally, by applying 
multiple regression analysis, negative correlation between miRNA-340 and PAIP1 protein 
expression was observed in lymphocytes. The role of PAIP1 specifically in blood cells is 
currently not understood. However, PAIP1 was described as an initiator of protein translation 
[165]. miRNA-340-dependent reduced PAIP1, present in our cohort, may control an 
adequate protein synthesis in blood cells.  
For identification of GDM-related metabolic stimuli contributing to elevated miRNA-
340 expression cell culture with primary lymphocytes was conducted within our study. A 
significant positive insulin effect on the expression of miRNA-340 was observed. The in-vitro 
findings are reflected by a positive correlation of maternal fasting insulin levels with miRNA-
340 expression in vivo. Primary cell culture conducted from non-pregnant women led to no 
marked expression differences upon insulin treatment. This result indicates that pregnancy-
associated factors may be permissive for this miRNA-340 expression inducing effect of 
insulin.  
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Finally, we investigated if WBC miRNA-340 expression could be a potential future 
indicator for adverse fetal programming of GDM offspring. Increased insulin and glucose 
levels in cord blood samples of children born from GDM pregnancies were reported [40, 166] 
and may lead to epigenetic differences in the fetal metabolism. However, we could not find 
any significant elevation of miRNA-340 in fetal WBC of newborns of GDM mothers. This 
finding proposes that metabolic stimuli contributing to miRNA-340 expression are different in 
mother and offspring. 
Additionally to the genome-wide sequencing of maternal WBC, miRNA pattern of 
maternal plasma of NGT and GDM women was conducted. Subjects who were included in 
the WBC sequencing group, donated plasma at the same time. Circulating miRNAs are 
discussed to originate from apoptotic cells from tissues with a high cellular turn over [167]. In 
the context of GDM, these tissues might be adipose tissue, liver, pancreas and/or placenta 
[112, 113, 168]. Furthermore, WBC are proposed to contribute to plasma miRNA content 
[167, 169]. In contrast to cancer-related plasma miRNAs [170], future studies need to 
investigate the predictive value of plasma miRNA in metabolic diseases such as diabetes. 
Although the origin of the 84 plasma miRNA negatively and the 52 plasma miRNA positively 
associated with maternal GDM is ultimately not clear, GDM associated differences of 
circulating miRNAs give insights in maternal disease progression [113] and also fetal 
programming [114]. Defined miRNAs are cell-type-specific. Differential plasma patterns may 
give insights in tissue-specific influences of GDM. Within the plasma miRNA dataset, we 
found both splicing variants of miRNA-199 to be more abundant in pregnant GDM women. 
Literature proposes these miRNAs to be tissue-specific indicators of pancreas [171] and liver 
[172, 173] dysfunction in diabetes. miRNA-92, also found to be more abundant in pregnant 
GDM women, was shown to be elevated in the placenta and plasma of pregnant women of 
macrosomic offspring [174]. MiRNAs are proposed to be taken up and released by the 
placenta. Therefore, maternally elevated abundance of miRNA-92 may give insights in fetal 
health or even fetal adverse programming.  
Finally, we found an elevated abundance of three members of the miRNA-let-7 family 
(let-7c, -d, and –f) in plasma of GDM women. As mentioned above, expression of this family 
is shown to respond to elevated glucose levels [162], also in WBC of GDM women (let-7c-
5p). Currently, the effects of maternally dysregulated plasma miRNAs on the placenta and 
the fetus are not understood. However, it is theoretically conceivable that GDM-associated 
elevation of miRNA-let-7 family members in the fetus of GDM women may contribute to the 
development of IR [162].  
We acknowledge limitations of the study. The effect of fatty acids on miRNA 
expression was not investigated. As differences of the lipid metabolism are of high relevance, 
this should be considered in future studies. Additionally, the putative reversibility of miRNA 
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derangement should be assessed in GDM follow-up investigations. Furthermore, regarding 
the findings of GDM-associated plasma miRNA, qPCR validation should be conducted in a 
bigger validation cohort. Moreover, all candidates found to be associated with GDM in 
maternal whole blood and plasma should be studied in placenta and fetal whole blood.   
In summary, our results provide evidence of miRNA-dependent programming of WBC 
related to GDM. The functional studies indicate that the GDM-related miRNA-340 responds 
to insulin and glucose in cultured lymphocytes and may therefore be of importance in 
hyperinsulinemia-induced differences in gene expression. PAIP1, a predicted target mRNA 
of miRNA-340, shows reduced mRNA expression related in maternal GDM. Furthermore, we 
could show, that GDM is associated with differences in the pattern of maternal cell-free 
miRNAs.  
In conclusion, we found potential future indicators of GDM based on WBC and 
plasma miRNA profiling. Future prospective studies focusing on the predictive value these 
indicators need to evaluate applicability.    
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Methods 
Participants and maternal and fetal blood collection 
From an ongoing pregnancy study, pregnant NGT and GDM women were selected and 
blood was collected during pregnancy (pregnancy week 27±2, Project l and ll NGT N=18; 
GDM N=18, Project lll screening: NGT N=8 and GDM N=8, validation: NGT N=30 and GDM 
N=30, plasma miRNA NGT N=9, GDM N=9). To compare findings in pregnant compared to 
non-pregnant women, blood was collected for lymphocyte isolation from the Tuebingen 
Family (TUEF) study [175]. For determination of the fetal cord-blood plasma lipid profile 
(Project l) samples of the pregnancy cohort were used (NGT N=11, GDM N=7). For 
quantification of fetal inflammatory parameters samples from the PEACHES cohort (NGT 
N=52, GDM N=52) [176] were available. Fetal cord blood collection was conducted at birth. 
Plasma was aliquoted immediately after blood collection. Samples were stored at -80°C. The 
pregnancy study and the PEACHES study were both approved by the local Ethic Boards and 
were performed in accordance with the ethical standards laid down in the Helsinki 
Declaration. Written informed consent was obtained from all study participants. Except of 16 
women of the PEACHES cohort, none of the women underwent insulin treatment. 
Characterization of participants was conducted by the physicians and clinical scientists of the 
Clinical Study Center University Hospital Tübingen, Regina Ensenauer and Sarah 
Perschbacher (Ludwig Maximillians University Munich and Heinrich Heine University 
Düsseldorf), and the group of Gernot Desoye (Medical University Graz).  
Oral glucose tolerance test and clinical chemical analyses 
The participants underwent a 5-point 75-g OGTT after overnight fasting. Venous blood 
samples were obtained at 0, 30, 60, 90, and 120min for determination of plasma glucose 
using a bedside glucose analyzer (YSI, Yellow Springs, OH, USA). GDM was diagnosed 
according to the IADPSG recommendations for the diagnosis and classification of 
hyperglycemia in pregnancy [55]. The PEACHES participants either had a 75-g OGTT or a 
50-g GCT (N=30) followed by a 75-g OGTT in case of a positive result (1-h glucose ≥7.8 
mmol/L) [177].  In Project lll, whole-body ISI was calculated for a defined group of 
participants. Therefore glucose and insulin values during the 5-point OGTT were collected 
and ISI was calculated as proposed by Matsuda and DeFronzo [178]: 
10,000/[c(Glc0)*c(Ins0)*c(Glcmean)* c(Insmean)]½(with c=concentration, Glc=glucose and 
Ins=insulin). For Project l and ll clinical data are shown in Table 1 (S.20). Study workflow and 
exclusion criteria are shown in supplemental Figure 1 (S.71). Clinical data and study 
workflow of Project lll are shown in Table 3 and 4 (S.32), and Figure 12 (S.31).  
Sampling of placental tissue and cord blood as well as characteristics of 
participants  
At delivery, placental tissue was collected strictly following a high-quality random sampling 
protocol [179, 180] (tissue with poor blood supply in proximity of the umbilical cord) and 
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extensively washed (4-10°C, 140mmol/l NaCl solution, for 30 seconds) immediately (NGT 
N=19; GDM N=11). Thereafter, tissue from the surface facing the fetal circulation was 
prepared. Tissue for lipid and protein analysis underwent another preparation (definition of 
quantity, other washing procedure, addition of proteinase and phosphatase inhibitors 
(complete and phosstop, Roche, Basel, Switzerland)) and was association with a reduction 
of available samples. Tissue was stored at -80°C until further analysis of RNA, proteins and 
lipids.  
Determination of the fatty acid profile of different lipid classes in 
placenta and maternal as well as fetal cord blood  
Maternal (NGT N=18; GDM N=18) and fetal cord blood plasma (NGT N=11; GDM N=7) as 
well as placental samples (NGT N=8, GDM N=8) were collected and processed for 
determination of lipid profiles by strictly following pre-analytical recommendations described 
earlier [181]. Placental samples were homogenized in PBS containing 1% Triton X-100 
(Sigma-Aldrich, Taufkirchen, Germany) with a Tissue Lyser (Qiagen, Hilden, Germany). 
Placental extracts and plasma samples were separated into five lipid subfractions, i.e., 
cholesteryl esters (CE), diacylglycerols (DG), NEFA, phospholipids (PL), and triacylglycerols 
(TG), using thin layer chromatography. Methodological details of thin layer chromatography 
and further determination of lipid profiles by gas chromatography were described earlier 
[182]. In total, 18 FAs were quantified (C14:0; C16:0, C16:1-n7, C18:0, C18:1-n7, C18:1-n9, 
C18:2-n6, C18:4-n3, C20:0, C20:3-n6, C20:4-n6, C22:0, C22:4-n6, C22:5-n3, C22:5-n6, 
C22:6-n3, C24:0, C24:1-n9). Experiments were conducted by Marketa Kovařova.   
Cell culture experiments 
In Project l and ll, primary trophoblasts were isolated from placentas of NGT and GDM 
women selected for similar maternal BMI (NGT N=7; GDM N=7). Isolation and quality control 
(human choriongonadotropin (β-hCG) release, cytokeratin 7 (CK7) (marker for 
syncytiotrophoblasts), vimentin (marker for fibroblasts), and histocompatibility antigen, class 
I, G–staining (widely expressed, however not in syncytiotrophoblasts) was conducted as 
described previously [183] [43]. We observed no reduction in β-hCG levels and only positive 
staining of the trophoblast-specific protein CK7 (supplemental Figure 7, S.73). After isolation, 
cells were kept in DMEM medium (Lonza, Basel, Switzerland) for 48h followed by a 24h 
stimulation with medium, 100µM palmitate or 100µM oleate (Sigma-Aldrich, Taufkirchen, 
Germany) coupled to 10% bovine serum albumin solution (BSA) (Sigma-Aldrich, 
Taufkirchen, Germany) and corresponding controls for 24h [109]. Cell culture supernatants 
were collected after 24-h of stimulation. In Project lll, human lymphocytes were isolated from 
heparinized venous blood samples during pregnancy week 24-32. Briefly, the heparinized 
blood was diluted with PBS (Lonza) in the ratio 1:1 and layered on Biocoll Separating 
Solution® (Biochrom). Afterwards, the sample was subjected to centrifugation (500g for 
20min). The white layer representing the lymphocytes was aspirated gently and transferred 
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aseptically to new tubes. The cell suspension was washed and cultured in sterile DMEM 
medium (GIBCO) with different glucose (5.5mM or 25mM) and insulin (Insuman Rapid, 
Sanofi) (10nM) concentrations. The medium was supplemented with 10% fetal bovine serum 
(Biochrom) and 1% penicillin-streptomycin (Lonza). The number of cells was adjusted to 
0.5×106 cells/well in 12-well plates. After 20-h incubation at 37°C, the cells were harvested.  
Total RNA isolation 
For Project l and ll, RNA was isolated from homogenized placental tissue (N=30) and 
trophoblasts (N=14) using miRNeasy (Qiagen). For Project lll, whole blood was collected in 
PAXgene Blood RNA Tubes (PreanalytiX) after overnight fasting. Total RNA was isolated 
using the Paxgene Blood miRNA kit (PreanalytiX) according to the manufacturer’s 
specifications. From freshly isolated and 20-h stimulated primary lymphocytes, total RNA 
was isolated with miRNeasy micro kit (Qiagen). The quality of the obtained WBC’s RNA was 
subsequently evaluated on the Agilent 2100 Bioanalyzer System. Samples with a RIN value 
≥ 8.0 were used for downstream library construction. 
miRNA isolation from maternal plasma 
During pregnancy week 27±2, maternal blood was collected after overnight fasting. Maternal 
plasma was stored till isolation of miRNAs at -80°C. For miRNA isolation, miRNeasy 
Serum/Plasma Kit (Qiagen, Hilden, Germany) was used with following adaptations proven to 
increase amounts of miRNA isolated: 400µl of stored plasma was thawn and centrifuged at 
14.000g for 10min at 4°C. Supernatant was mixed with 1.2ml TRI Reagent LS (Sigma-
Aldrich, St. Louis, USA), gently vortexed for 10sec followed by 10min of incubation at room 
temperature (RT). As glycogen is proposed to be a carrier of miRNA, 1.2µl of a 10mg/ml 
glycogen solution were added to each sample. After addition of 320µl chloroform, samples 
were again vortexed for 45sec and incubated for 5min at RT. Finally, following the 
manufactures’ recommendations for the rest of the procedure, samples were centrifuged at 
14.000g for 20min at 4°C. miRNA was eluated two times with 15µl water.  
cDNA synthesis and quantitative PCR (qPCR) 
mRNA expression of CRY2, FABP3, FABP4, FAT, GRB10, ID2, IL1B, IL6, IL8, LIPG, LPL, 
PAIP1, PITPNB, PLIN2, SCARB, SPRY3, TNF-α, TLR2, TLR4 and the house keeping gene 
RPS13 was determined on the Light Cycler 450 (Roche) as shown earlier [184]. For mRNA 
qPCR, 2.5ng of cDNA was used. RPS13 was shown to be stably expressed in trophoblasts 
of NGT and GDM women and not influenced by maternal BMI (data not shown). ∆∆Cq values 
are shown when mRNA expression of treated cells is given relative to a control condition, 
i.e., mRNA expression of untreated cells. ∆Cq values are shown to compare basal mRNA 
expression, normalized to a housekeeping gene. Reverse transcription of miRNA was 
conducted as recommended by the manufacturer. Briefly, 500ng total RNA was reversely 
transcribed with 5x miScript HiFlex Buffer (miScript ll RT kit, Qiagen) under following 
conditions: 37°C for 60min, 95°C for 15min, immediately on ice. This was followed by qPCR 
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(miScript SYBR Green PCR kit, Qiagen). QPCR measurements of both miRNAs and mRNAs 
were conducted in duplicates. For miRNA qPCR, 10ng cDNA were used. Expression of 
miRNA-19a-3p (MIMAT0000073), miRNA-19b-3p (MIMAT0000074), miRNA-142-5p 
(MIMAT0000433), miRNA-143-3p (MIMAT0000435), let-7g-5p (MIMAT0000414), miRNA-
340-5p (MIMAT0000750), and the house keeping gene U6 small nuclear 6, (RNU6B) was 
determined on a LightCycler 450 (Roche) in following conditions: activation 95°C for 15min, 
quantification (45 cycles) 94°C for 15sec, 55°C for 30sec, 70°C for 30sec. In order to control 
for primer specificity, a melting curve was performed. Primer sequences and fluorescent 
probes are shown in supplemental Table 7 (S. 82). 
Library preparation and RNA sequencing  
NEBNext small RNA library Prep Set for Illumina and NuGen Ovation RNA-Seq system v2 
were used according to the manufacturer’s recommendations to generate small and long 
RNA-Seq libraries. For long RNA-Seq, the obtained cDNAs were sheared with a Covaris 
Focused-ultrasonicator prior to adaptor ligation. Finally, libraries were sequenced on an 
Illumina HiSeq2500 platform by Peter Huypens.  
Cytokine, chemokine, and APL quantification from placental tissue, cell 
culture supernatant and fetal sera 
Placental tissue pieces were extensively washed with cold PBS and recommended 
concentrations of proteinase and phosphatase inhibitors (complete and phosstop, Roche, 
Basel, Switzerland) and stored at -80°C till further processing (NGT N=6; GDM N=6). Tissue 
pieces (50mg) were homogenized by Qiashredder (Qiagen, Hilden, Germany) and 
ultrasound in protein lysis buffer (10nM Tris containing complete and phosstop, pH 7.4). 
Total protein concentrations were determined with Pierce BCA Protein Assay Kit 
(Thermofisher, Waltham, USA). Placental IL1B, IL6 and IL8 protein levels were quantified 
using Quantikine HS ELISA (R&D, Minneapolis, USA). For IL1B and IL8 undiluted protein 
lysates and for IL6 protein lysates diluted 1:10 were used. Quantification was conducted in 
duplicates and protein concentrations were normalized for total cellular protein. Cytokine and 
chemokine concentrations in undiluted primary trophoblast cell culture supernatants were 
quantified using Quantikine HS ELISA (R&D, Minneapolis, USA, NGT N=7; GDM N=7). 
Inflammatory cytokines in fetal cord blood sera were quantified using Bio-Plex Pro Human 
Cytokine-27-plex Kit (BioRad Laboratories, Biorad, Hercules, USA) following the 
manufacturers’ recommendations (diluted 1:4). Each pair selected based on maternal BMI 
(NGT N=52; GDM N=52) was run on one plate to avoid inter-assay variance. Concentrations 
outside the standard curve were not considered for statistical analysis leading to reduced 
sample sizes: Granulocytecolony stimulating factor (G-CSF) (N=56), GM-CSF (N=53), IL6 
(N=57), and IL15 (N=65), interferone (IFN)-γ (N=71), IL8 (N=98), MIP-1α (N=96), regulated 
on activation (RANTES) (N=58), and vascular endothelial growth factor (VEGF) (N=67). 
Quantification of APL in cell culture supernatant and fetal sera was conducted with an ELISA 
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(Phoenix Pharmaceuticals, CA, USA). Following the recommendations of the manufacturer 
sera were diluted 1:4. Cell culture supernatants were not diluted. 
Protein visualization and quantification by Western blot 
For Project l and ll, placental tissue was shredded and homogenized in a protein lysis buffer 
(50mM Hepes, pH 7.0), 150mM NaCl, 1.5mM MgCl2, 0.1mM EGTA, 10% glycerol, 1% Triton 
x-100) (Roth, Karlsruhe, Germany). The proteins from tissue and cell lysates (50μg) were 
resolved on a 7.5% or 10% Tris-HCl gel and blotted onto nitrocellulose membranes. For 
Project lll, primary lymphocytes were isolated as described above and washed in PBS 
(Lonza, Basel, Switzerland). Protein isolation was conducted with AllPrep DNA/RNA/Protein 
Mini Kit (Qiagen, Hilden, Germany) and protein was solved in Lämmli buffer containing 
62.5mM Tris, pH 6.8), 2% SDS, 10% Glycin, and 3% beta-mercaptoethanol. Protein 
concentrations were determined with Qubit Protein Assay Kit (Thermo Fisher Scientific, 
Dreieich, Germany). Unspecific binding sites were blocked with 5% dry milk powder in TBS-
Tween prior to overnight incubation with primary monoclonal TLR2 (1:500, Abcam, 
Cambridge, England) or monoclonal APJ (1µg/ml, Merck-Millipore, Darmstadt, Germany) or 
polyclonal GRB10 and monoclonal PAIP1 (1:1000 Abcam, Cambridge, UK, both) antibody. 
GAPDH (1:1000; Sigma Aldrich, St. Louis, USA) was used as loading control. The incubation 
with primary antibody was followed by 1-h incubation with a HRP-coupled secondary 
antibody (1:3000). Antibodies were diluted in 5% dry milk powder in TBS-Tween. Protein 
bands were detected and quantified with Chemidoc touch Image lab software (Biorad, 
Hercules, USA).  
Quantification of macrophages 
Paraffin-embedded, serial sections of placental tissue (NGT N=3; GDM N=3, selected based 
on fetal sex and maternal BMI) were incubated with a primary monoclonal antibody against 
CD68 (1:3000, clone KP-1, Dako, Jena, Germany) (brown staining). The primary antibody 
was detected using the Opti-View system (Roche-Ventana, Multimer Technology, Basel, 
Switzerland). Haematoxylin-eosin staining was used as counterstaining. Immune cell 
infiltration of the villous stroma was quantified by counting CD68-positive villi in a blinded 
manner. In more detail, intermediate villi similar in size and area from morphological 
comparable sections of placental tissue slides were selected. From each placenta, four 
pictures from three slides were used for quantification. Percentage of CD68-positive 
placental villi related to the total amount of selected villi was calculated. 
Statistical analysis 
Project l and ll 
Data are presented as individual data, means +/- SD, or means +/- SEM as indicated. 
Multiple linear regression analysis was conducted for all ex-vivo experiments. We used 
maternal BMI, gestational age, fetal sex as confounding covariates, and GDM vs NGT as 
independent variable. To avoid overadjustment, small subgroups of BMI- and fetal sex-
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matched samples (CD68-quantification) were analyzed with adjustment for gestational age, 
only. The descriptive clinical data presented in Table 3 and 4 (S.32) were analyzed by two-
tailed Student’s t-test. The data from in-vitro cell culture experiments were analyzed by one-
tailed Student’s t-test (two-group comparisons) or analysis of variance (ANOVA) with 
Dunnett’s post-hoc test (three- and more-group comparisons). Differences with P≤0.05 were 
considered statistically significant. 
Project lll  
For RNA sequencing, raw read counts for miRNAs and mRNAs were generated by 
overlapping the positions of the mapped reads with annotations obtained from miRbase (doi: 
10.1093/nar/gkt1114) and RefSeq, (doi: 10.1093/bioinformatics/btp616) respectively. 
Statistical analysis of the read counts can be found at the NCBI Gene Expression Omnibus 
(GEO record: GSE92772) and were conducted using the edgeR (doi: 
10.1093/bioinformatics/btp616) package for R. For the identification of GDM-related 
differential expression of sncRNAs, lncRNAs, and mRNAs, in the screening group and 
validation group, a paired analysis (two-tailed Student’s t-test) was conducted after 
adjustment for pregnancy week and maternal weight gain within the first half of the 
pregnancy. For this paired analysis, P-values<0.05 and FDR<0.1 were considered as 
significant. For visualization of the results of the screening group, an interaction network 
analysis was performed. Based on miRNA-mRNA in silico target site predictions obtained 
from Target Scan (version 6.2) (doi: 10.1016/j.cell.2004.12.035), the previously described 
miRlastic R approach for the identification of potential regulatory interactions between 
significantly regulated miRNAs and mRNAs by incorporating their expression profiles was 
applied [185]. Briefly, elastic net regression was used for performing feature selection on a 
set sequence-based target predictions to identify inversely regulated miRNA-target 
relationships. For qPCR validation experiments within the validation and cord blood group, 
paired two-tailed Student’s t-tests were conducted (JMP, SAS, Cary, USA). In cases where 
the direction of expected differences was defined by earlier experiments one-tailed paired 
Student’s t-tests were conducted (JMP, SAS, Cary, USA). Using univariate linear regression 
analysis, WBC miRNA-340 expression was correlated with maternal fasting glucose and 
insulin levels. Applying multiple linear regression, lymphocyte miRNA-340 expression was 
correlated with PAIP1 mRNA and protein expression after correction for two batches of 
sample preparation (JMP, SAS, Cary, USA). To this end the batch was introduced as dummy 
variable in the multiple linear regression models. In order to investigate effects of maternal 
BMI, an unpaired analysis of the results from the screening group was conducted, by multiple 
linear regression analysis. Adjustments for this secondary analysis were maternal GDM, 
maternal age, weight gain, and pregnancy week. All computational analysis of the WBC 
subproject, were conducted by Steffen Sass. 
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For analysis of differential GDM-related abundance of plasma miRNAs, we followed the 
recommendation of the bioinformatician Richa Batra conducting the multiple regression 
analysis adjusting for maternal age, BMI, weight gain, fetal sex, and gestational age at time 
of blood collection (pregnancy week 27±2).  
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Zusammenfassung  
Projekt l und ll der vorliegenden Arbeit beschäftigen sich mit Auswirkungen von 
Gestationsdiabetes (GDM) auf die zukünftige Gesundheit des Kindes. Epidemiologische 
Studien weisen darauf hin, dass mütterlicher GDM das spätere Risiko für Übergewicht und 
Diabetes beim Kind erhöht. Weitere Ergebnisse weisen darauf hin, dass Feten von GDM-
Müttern bereits in utero eine Insulinsresistenz (IR) des Gehirns entwickeln, was ursächlich 
für die spätere Entwicklung von Typ-2-Diabetes sein könnte.  
Ziel dieser Projekte war es plazentale und fetale Veränderungen in Abhängigkeit von 
mütterlichem GDM zu identifizieren. Zunächst wurden Lipidprofile des mütterlichen Blutes 
und der Plazenta von normal glucosetoleranten (NGT) und GDM-Frauen erstellt. Dabei 
konnte gezeigt werden, dass sich erhöhte Mengen an gesättigten Fettsäuren (ges. FS; z.B.: 
Palmitat) aus dem mütterlichen Blut in plazentalem Gewebe wiederfinden. Ebenfalls konnte 
gezeigt werden, dass GDM mit einer erhöhten plazentalen Expression von PLIN2, 
inflammatorischen Genen (TLR2, IL1B, und IL6) und Apelin (APL) sowie seinem Rezeptor 
APJ einhergeht. Der Vergleich der Expression dieser Gene in primären Trophoblasten 
isoliert aus NGT und GDM-Frauen spiegelt die plazentalen Befunde wieder. Zudem führt die 
Stimulation von primären Trophoblasten mit Palmitat zu einer erhöhten Expression von 
PLIN2 und der inflammatorischen Gene sowie APJ. Außerdem ist GDM mit einer erhöhten 
Einwanderung von Makrophagen in die Plazenta assoziiert. Dies könnte auf eine gesteigerte 
IL8-Expression zurückzuführen sein. Abschließend wurde untersucht ob sich GDM-
assoziierte Veränderungen der Plazenta im fetalen Blut wiederfinden und damit zur 
intrauterinen Programmierung beitragen könnten. Dabei wurden weder signifikant erhöhte 
Mengen an ges. FS, noch erhöhte Konzentrationen von Zytokinen oder APL im 
Nabelschnurblut von Neugeborenen der GDM-Mütter gefunden. Dies deutet darauf hin, dass 
andere Mechanismen an der Entwicklung der intrauterinen Insulinresistenz beteiligt sind.  
 Neben direkten metabolischen Einflüssen auf die Plazenta und den fetalen 
Metabolismus wurde untersucht ob es im Blut von Schwangeren mit GDM zu epigenetischen 
Veränderungen kommt. Zunächst wurde das miRNA-Expressionsprofil von Blutzellen aus 
NGT und GDM-Frauen verglichen. In mütterlichen Blutzellen konnte dabei eine erhöhte 
Expression von miRNA-340 identifiziert werden. In-vitro-Ergebnisse zeigen, dass Insulin die 
Expression dieser miRNA steigert. Auch in vivo gibt es eine positive Korrelation der 
Plasmainsulinwerte mit der Expression von miRNA-340 in Blutzellen. Zusätzlich wurde der 
Einfluss dieser dysregulierten miRNA auf mögliche Zielgene untersucht. Dabei konnte eine 
negative Korrelation zwischen der miRNA-340 Expression und des PAIP1-Proteins in 
mütterlichen Lymphocyten gezeigt werden. In mütterlichem Plasma konnten ebenfalls GDM-
assoziierte miRNA-Expressionsmuster gefunden werden. Folgestudien sollten nun den 
prädiktiven Wert dieser miRNAs als mögliche neue Marker für GDM untersuchen. 
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Summary 
Project 1 and 2 focus on the influence of maternal gestational diabetes (GDM) on fetal future 
health. Epidemiological data indicate that offspring of pregnancies accompanied by maternal 
GDM have elevated risk of developing overweight and type 2 diabetes (T2D) later in life. 
Recent results propose that fetal insulin resistance (IR) exists already in utero and could be 
causative for development of overweight and T2D later.  
Scientific goal of these projects was to investigate placental GDM-associated 
alterations contributing to fetal programming. Maternal plasma and placental lipid profiles 
were prepared. These profiles indicate that elevated amounts of saturated non-esterified fatty 
acids (SFA, i.e. palmitate) of the maternal circulation can be found in placental tissue and 
contribute to an elevated placental gene expression of PLIN2 and inflammatory genes 
(TLR2, IL1B, and IL6). Gene expression of these genes in primary trophoblasts isolated from 
NGT and GDM women resembles expression in whole placental tissue. Furthermore, 
stimulation of primary trophoblasts with palmitate leads to increased gene expression of 
PLIN2, inflammatory genes, apelin (APL) and it’s receptor APJ. Additionally, GDM was 
shown to be associated with an elevated placental macrophage accumulation. This finding 
may result from elevated SFA-mediated IL8 expression in placenta of GDM women. Finally, 
we investigated if GDM-associated alterations of placental lipid profiles and gene expression 
contribute to differences of cord blood lipid and inflammatory cytokine concentrations or 
differences in cord blood APL concentrations. As no GDM-associated elevated fetal plasma 
SFA and inflammatory cytokine concentrations or differences of APL concentration were 
found we propose that other mechanisms could contribute to GDM-associated development 
of in-utero IR. 
 In conclusion, our results indicate that GDM-associated alterations do not directly 
influence fetal metabolism. In-utero development of fetal IR may therefore result from other 
mechanisms. 
Additionally to direct metabolic influences of GDM on the placenta and the fetal metabolism, 
we investigated if epigenetic differences in maternal blood are associated with GDM. 
Therefore, the miRNA expression profile of maternal blood was compared between NGT and 
GDM women. An elevated expression of miRNA-340 could be found in maternal whole blood 
cells (WBC). In-vitro results of this project indicate that insulin increases the expression of 
this miRNA. Furthermore, a positive correlation between maternal plasma insulin and WBC 
miRNA-340 is observed. Additionally the influence of the differentially expressed miRNA on 
poteintial target genes was investigated. A negative correlation between miRNA-340 
expression and PAIP1 protein expression in lymphocytes was seen. In maternal cell-free 
plasma, further GDM-associated miRNA expression patterns are present. Future studies 
should investigate the predictive value of these new GDM-associated indicators. 
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Supplemental Figure 1: Available samples and conducted experiments in each cohort are indicated. 
 
 
 
 
 
Supplemental Figure 2: Non-esterified fatty acids (NEFA) in mother, placenta and fetus. Saturated (SFA), mono-
unsaturated (MUFA) and poly-unsaturated (PUFA) NEFA-profile in (A) maternal plasma (NGT N=18; GDM N=18), (B) placental 
tissue (NGT N=19; GDM N=11), and (C) fetal cord blood (NGT N=11; GDM N=7). Shown are means ± SEM. White columns 
show results of NGT and black columns of GDM women. For analysis of maternal NEFA profile fetal sex was not considered as 
confounder (confounding covariates: BMI, gestational age). Significant differences (P≤0.05) are marked with bold fonts. 
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Supplemental Figure 3: Gene expression in whole placental tissue. (A-I) mRNA expression of FABP4, FAT, LIPG, LPL, 
PLIN2 SLC27A1, SLC27A4, TLR4, and TNF-α in placental tissue of normal glucose tolerant (NGT N≥9) and gestational 
diabetes (GDM N≥8) women 
 
 
 
 
 
 
 
Supplemental Figure 4: Protein expression of TLR2 and GAPDH by Western blotting. For protein quantification, protein 
was isolated from placental tissue of normal glucose tolerant (NGT N=6) and gestational diabetes (GDM N=6) women. Samples 
were selected based on maternal body mass index.  
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Supplemental Figure 5: Protein expression of GRB10 and PAIP1 in lymphocytes. For protein quantification, protein was 
isolated from lymphocytes of normal glucose tolerant (NGT N=15) and gestational diabetes (GDM N=15) women. Samples were 
paired based on maternal age and body mass index. (A) Western blots with antibodies against GRB10 and PAIP and the 
reference gene GAPDH. Protein expression of (B) GRB10 and (C) PAIP1 after normalization with GAPDH. Shown are means ± 
SD. 
 
 
 
 
 
 
  
 
  
 
Supplemental Figure 6: Expression of miRNA-340 in fetal cord blood WBC. miRNA-340 expression in cord blood WBC of 
children each born from maternal NGT (mNGT) and maternal GDM (mGDM) (N=8, each) pregnancies was investigated. 
Samples were paired based on birth size and fetal sex. Shown are the means ± SD. 
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Supplemental Figure 7: Quality control of primary trophoblasts. (A) Human choriongonadotropin (β-hCG) values of primary 
trophoblasts (N=7) after 24h, 48h, 72h and 96h in cell culture supernatant. Immunocytochemical staining of primary trophoblasts with 
antibody against (B) cytokeratin 7 (CK7) a trophoblast-specific marker, (C) vimentin and (D) histocompatibility antigen, class I, G (HLAG). 
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Supplemental Table 1: Lipid profile of placental tissue of NGT and GDM women. Placental lipid profile of normal 
glucose tolerant (NGT N=8) and gestational diabetes (GDM N=8) women was compared. Placental extracts were separated into 
five lipid subfractions, i.e., cholesterol ester (CE), diacylglycerol (DG), non-esterified fatty acid (NEFA), phospholipid (PL), and 
triacylglycerol (TG). All data are given as absolute numbers or means ± SD. Significant differences (P<0.05) are indicated in 
bold fonts. 
  CE DG NEFA PL TG 
  NGT GDM NGT GDM NGT GDM NGT GDM NGT GDM 
C14:0 [%] 5.45±2.86 4.17±2.21 1.37±0.36 1.62±0.25 2.78±1.01 3.4±1.34 0.45±0.12 0.52±0.23 5.43±1.63 4.09±1.87 
C16:0 [%] 26.46±8.71 25.37±5.41 28.58±1.45 29.15±2.69 26.08±2.42 30.02±2.28 19.09±1.02 20.51±3.26 33.15±3.03 31.06±2.81 
C16:1-n7 [%] 1.67±0.93 1.02±0.35 1.70±1.07 1.55±1.02 0.43±0.11 0.46±0.08 0,19±0.09 0.26±0,10 1.37±0.36 1.46±0.11 
C18:0 [%] 19.25±8.01 19.94±6.88 18.65±1.8 19.34±2.17 17.57±3.81 25.28±4.82 14.92±0.65 16.19±2.79 17.87±7.89 17.05±4.07 
C18:1-n7-cis [%] 0.9±0.37 1.62±1.92 1.13±0.17 1.05±0.27 1.57±0.29 1.25±0.45 1.66±0.27 1.56±0.26 1.83±0.62 2.04±0.61 
C18:1-n9 [%] 8.56±3.34 8.95±3.96 5.46±0.57 5.84±1.80 9.27±3.19 8.11±1.80 8.19±0.74 7.84±0.99 17.15±9.21 19.24±6.81 
C18:2-n6 [%] 21.29±14.74 22.25±9.25 5.91±0.69 5.04±1.98 9.64±2.00 7.86±2.21 9.77±1.03 9.56±1.79 9.08±4.79 10.48±2.49 
C18:4-n3 [%] 2.54±1.30 1.56±0.61 0.13±0.04 0.17±0.07 1.62±1.10 1.27±0.57 0.14±0.09 0.32±0.41 2.48±1.86 1.87±1.08 
C20:0 [%] 0.49±0.22 0.48±0.19 0.5±0.09 0.52±0.17 0.34±0.16 0.45±0.08 0.21±0.04 0.31±0.16 0.47±0.23 0.40±0.25 
C20:3-n6 [%] 7.07±2.37 7.31±2.43 7.49±2.84 7.07±3.02 5.91±2.02 5.11±1.69 7.31±1.76 5.85±1.16 3.93±2.94 3.87±1.41 
C20:4-n6 [%] 4.93±4.43 5.06±3.03 27.73±.1.62 26.68±7.38 15.98±4.08 11.96±4.43 26.35±1.80 25.84±6.02 4.23±1.86 5.30±2.74 
C22:0 [%] 0.31±0.14 0.28±0.10 0.05±0.02 0.10±0.04 0.22±0.09 0.20±0.13 0.71±0.12 0.88±0.29 0.29±0.14 0.27±0.11 
C22:4-n6 [%] 0.62±0.19 0.59±0.31 0.69±0.12 0.57±0.24 3.07±1.78 1.66±1.49 2.10±0.52 2.00±0.31 0.93±0.52 0.80±0.25 
C22:5-n3 [%] 0.23±0.09 0.29±0.15 0.10±0.05 0.15±0.06 0.24±0.07 0.21±0.10 0.41±0.08 0.41±0.11 0.30±0.14 0.30±0.12 
C22:5-n6 [%] 0.44±0.19 0.49±0.14 0.31±0.07 0.40±0.16 0.71±0.17 0.70±0.25 0.97±0.26 0.86±0.25 0.48±0.32 0.45±0.20 
C22:6-n3 [%] 0.75±0.15 0.87±0.35 1.55±0.51 1.85±0.76 3.34±1.60 2.02±0.75 6.10±1.29 5.28±1.32 1.49±0.99 2.06±1.19 
C24:0 [%] 0.30±0.08 0.34±0.17 0.13±0.05 0.20±0.09 0.19±0.07 0.24±0.10 0.86±0.17 1.05±0.84 0.41±0.29 0.30±0.18 
C24:1-n9 [%] 0.40±0.11 0.44±0.14 0.24±0.14 0.26±0.12 0.22±0.11 0.25±0.10 0.77±0.15 1.02±0.59 0.49±0.37 0.42±0.22 
MUFA [%] 9.87±3.49 11.00±3.66 6.83±0.72 7.15±2.00 11.06±3.42 9.61±2.06 0.11±0.01 0.10±0.02 19.46±9.54 21.70±6.97 
PUFA [%] 37.64±16.90 38.14±11.18 43.9±2.16 41.92±4.56 40.73±6.42 31.04±6.26 0.54±0.01 0.51±0.08 22.91±5.14 25.12±5.10 
SFA [%] 51.77±19.24 50.08±13.52 49.27±2.43 50.93±4.39 47.18±6.71 59.60±7.45 0.36±0.01 0.39±0.07 57.63±12.73 53.18±8.18 
 
 
Supplemental Table 2: mRNAs negatively associated with maternal GDM in whole blood cells of the 
screening group. Supplemental Table 2 shows miRNAs significantly (P<0.05; false discovery rate (FDR)<0.1) negative 
associated with GDM. A paired analysis was conducted and adjusted for maternal weight gain and pregnancy week. mRNAs 
are sorted by fold change (FC), shown in the 3rd column. Logarithmic counts per million (logCPM), indicating the relative 
abundance of the transcript, are shown in the 4th column of the table. P-values and false discovery rates (FDR) are indicated in 
the 5th and 6th column. 
Symbol Name FC logCPM P FDR 
SFMBT2 Scm-like with four mbt domains 2 0.507 3.309 1.22E-03 0.095 
FAIM3 Fas apoptotic inhibitory molecule 3 0.505 5.313 7.18E-04 0.072 
LOC100272216 uncharacterized LOC100272216 0.500 5.703 1.06E-03 0.091 
CTSW cathepsin W 0.494 3.278 9.91E-04 0.090 
LILRB1 leukocyte immunoglobulin-like receptor, subfamily B (with TM and 
ITIM domains), member 1 
0.491 5.151 3.21E-04 0.057 
CD163 CD163 molecule 0.491 2.798 1.31E-03 0.098 
ZXDB zinc finger, X-linked, duplicated B 0.481 2.388 1.15E-03 0.093 
LOC441081 POM121 membrane glycoprotein (rat) pseudogene 0.479 7.214 3.96E-04 0.062 
ZMAT1 zinc finger, matrin-type 1 0.478 2.947 6.28E-04 0.070 
NLRP2 NLR family, pyrin domain containing 2 0.476 3.708 5.77E-04 0.070 
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LOC100288778 WAS protein family homolog 1 pseudogene 0.475 3.146 6.15E-04 0.070 
HLA-DMB major histocompatibility complex, class II, DM beta 0.473 4.998 2.55E-04 0.052 
TAS2R40 taste receptor, type 2, member 40 0.473 2.630 1.07E-03 0.091 
NUTM2G NUT family member 2G 0.467 2.241 1.05E-03 0.091 
TTI1 TELO2 interacting protein 1 0.466 2.294 1.00E-03 0.090 
TERF1 telomeric repeat binding factor (NIMA-interacting) 1 0.464 2.368 7.99E-04 0.077 
HLA-DMA major histocompatibility complex, class II, DM alpha 0.462 5.675 1.27E-04 0.049 
ATAT1 alpha tubulin acetyltransferase 1 0.455 3.310 2.12E-04 0.052 
MOV10 Mov10 RISC complex RNA helicase 0.454 1.977 1.12E-03 0.093 
ABCG1 ATP-binding cassette, sub-family G (WHITE), member 1 0.453 1.887 1.22E-03 0.095 
ZBTB25 zinc finger and BTB domain containing 25 0.450 3.026 2.78E-04 0.052 
GPRASP1 G protein-coupled receptor associated sorting protein 1 0.449 1.931 1.03E-03 0.091 
ADGRL1 adhesion G protein-coupled receptor L1 0.448 2.225 5.59E-04 0.069 
PRPF31 pre-mRNA processing factor 31 0.446 3.825 1.36E-04 0.049 
TSPAN3 tetraspanin 3 0.446 2.770 2.36E-04 0.052 
VSTM1 V-set and transmembrane domain containing 1 0.446 4.128 1.62E-04 0.052 
TNFSF12 tumor necrosis factor (ligand) superfamily, member 12 0.446 1.957 6.85E-04 0.071 
RUNDC1 RUN domain containing 1 0.445 2.148 5.48E-04 0.069 
TTBK2 tau tubulin kinase 2 0.444 1.971 6.64E-04 0.071 
SFXN3 sideroflexin 3 0.443 1.589 1.29E-03 0.098 
LMO7 LIM domain 7 0.443 2.073 4.83E-04 0.066 
IGLL5 immunoglobulin lambda-like polypeptide 5 0.441 3.061 3.72E-04 0.059 
TYW1 tRNA-yW synthesizing protein 1 homolog (S, cerevisiae) 0.440 2.195 4.61E-04 0.065 
TXNDC5 thioredoxin domain containing 5 (endoplasmic reticulum) 0.438 2.072 6.50E-04 0.071 
KIF5C kinesin family member 5C 0.438 1.973 5.53E-04 0.069 
ARL17A ADP-ribosylation factor-like 17A 0.438 7.587 3.00E-05 0.024 
WDR46 WD repeat domain 46 0.433 3.313 1.22E-04 0.049 
FER fer (fps/fes related) tyrosine kinase 0.432 1.709 1.07E-03 0.091 
CD40LG CD40 ligand 0.431 2.076 4.94E-04 0.066 
LHX4-AS1 LHX4 antisense RNA 1 0.429 2.390 2.09E-04 0.052 
NAAA N-acylethanolamine acid amidase 0.424 3.089 8.08E-05 0.041 
GEMIN5 gem (nuclear organelle) associated protein 5 0.424 1.764 6.21E-04 0.070 
RHOF ras homolog family member F (in filopodia) 0.423 1.482 1.26E-03 0.097 
SH3PXD2A SH3 and PX domains 2A 0.419 2.019 4.66E-04 0.065 
MTHFD1 methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1, 
methenyltetrahydrofolate cyclohydrolase, formyltetrahydrofolate 
synthetase 
0.419 1.612 5.67E-04 0.069 
ZBTB22 zinc finger and BTB domain containing 22 0.414 2.056 2.58E-04 0.052 
ST3GAL4-AS1 ST3GAL4 antisense RNA 1 (head to head) 0.414 2.015 5.36E-04 0.069 
TRMT44 tRNA methyltransferase 44 homolog (S, cerevisiae) 0.414 1.197 1.14E-03 0.093 
RING1 ring finger protein 1 0.413 3.144 4.42E-05 0.029 
GTF2E1 general transcription factor IIE, polypeptide 1, alpha 56kDa 0.411 1.083 1.14E-03 0.093 
RDH13 retinol dehydrogenase 13 (all-trans/9-cis) 0.410 4.235 3.31E-05 0.024 
ZNF765 zinc finger protein 765 0.409 1.016 1.20E-03 0.095 
TUBGCP5 tubulin, gamma complex associated protein 5 0.406 2.407 8.88E-05 0.043 
RHD Rh blood group, D antigen 0.403 2.908 2.16E-04 0.052 
PRR29 proline rich 29 0.403 1.702 4.88E-04 0.066 
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ARL17B ADP-ribosylation factor-like 17B 0.402 4.903 7.52E-06 0.009 
SERF1B small EDRK-rich factor 1B (centromeric) 0.400 2.490 1.88E-04 0.052 
SERF1A small EDRK-rich factor 1A (telomeric) 0.400 2.490 1.88E-04 0.052 
ZNF772 zinc finger protein 772 0.397 1.076 8.39E-04 0.080 
DDX56 DEAD (Asp-Glu-Ala-Asp) box helicase 56 0.397 1.736 2.25E-04 0.052 
RFX5 regulatory factor X, 5 (influences HLA class II expression) 0.396 1.944 1.26E-04 0.049 
CCDC77 coiled-coil domain containing 77 0.396 1.047 1.17E-03 0.094 
TTC27 tetratricopeptide repeat domain 27 0.395 1.591 2.77E-04 0.052 
MED22 mediator complex subunit 22 0.395 1.404 7.10E-04 0.072 
GLMP glycosylated lysosomal membrane protein 0.395 0.933 1.37E-03 0.099 
PAAF1 proteasomal ATPase-associated factor 1 0.394 0.690 1.37E-03 0.099 
RASGRP3 RAS guanyl releasing protein 3 (calcium and DAG-regulated) 0.393 1.974 2.11E-04 0.052 
LOC100505549 uncharacterized LOC100505549 0.392 1.567 2.44E-04 0.052 
KAT2A K(lysine) acetyltransferase 2A 0.390 0.695 1.32E-03 0.098 
MPI mannose phosphate isomerase 0.385 1.383 5.94E-04 0.070 
SNAPC5 small nuclear RNA activating complex, polypeptide 5, 19kDa 0.385 1.038 6.58E-04 0.071 
LOC100133315 transient receptor potential cation channel, subfamily C, member 
2-like 
0.384 0.825 9.48E-04 0.087 
CCHCR1 coiled-coil alpha-helical rod protein 1 0.381 1.425 4.49E-04 0.065 
CXXC5 CXXC finger protein 5 0.380 1.305 2.82E-04 0.052 
ENTPD6 ectonucleoside triphosphate diphosphohydrolase 6 (putative) 0.380 1.173 5.38E-04 0.069 
USP21 ubiquitin specific peptidase 21 0.379 1.280 3.50E-04 0.058 
KRBA2 KRAB-A domain containing 2 0.376 0.925 7.42E-04 0.074 
MLYCD malonyl-CoA decarboxylase 0.375 0.567 1.03E-03 0.091 
MYO1E myosin IE 0.375 1.104 7.19E-04 0.072 
NR1D1 nuclear receptor subfamily 1, group D, member 1 0.373 1.215 3.12E-04 0.056 
NCR1 natural cytotoxicity triggering receptor 1 0.371 1.268 7.15E-04 0.072 
RIN2 Ras and Rab interactor 2 0.369 1.058 3.74E-04 0.059 
SLC4A10 solute carrier family 4, sodium bicarbonate transporter, member 
10 
0.368 1.681 1.39E-04 0.049 
LILRA4 leukocyte immunoglobulin-like receptor, subfamily A (with TM 
domain), member 4 
0.368 1.416 6.49E-04 0.071 
SNAPIN SNAP-associated protein 0.365 1.040 6.54E-04 0.071 
SERGEF secretion regulating guanine nucleotide exchange factor 0.365 0.694 7.86E-04 0.077 
CD72 CD72 molecule 0.362 0.830 6.04E-04 0.070 
ZNF544 zinc finger protein 544 0.362 0.774 6.26E-04 0.070 
PRIM1 primase, DNA, polypeptide 1 (49kDa) 0.362 1.246 4.10E-04 0.062 
LCMT2 leucine carboxyl methyltransferase 2 0.359 0.167 1.39E-03 0.099 
PCDH12 protocadherin 12 0.358 0.651 1.25E-03 0.096 
CENPO centromere protein O 0.358 0.729 6.84E-04 0.071 
DEXI Dexi homolog (mouse) 0.355 0.500 1.20E-03 0.095 
LOC101927354 uncharacterized LOC101927354 0.354 -0.514 1.36E-03 0.099 
ZNF304 zinc finger protein 304 0.353 0.359 1.13E-03 0.093 
TRIM35 tripartite motif containing 35 0.352 1.792 5.03E-05 0.029 
IL21R-AS1 IL21R antisense RNA 1 0.351 1.149 2.03E-04 0.052 
CD79A CD79a molecule, immunoglobulin-associated alpha 0.350 1.188 2.80E-04 0.052 
IGSF8 immunoglobulin superfamily, member 8 0.349 -0.032 1.28E-03 0.098 
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ERI2 ERI1 exoribonuclease family member 2 0.349 -0.104 1.04E-03 0.091 
DNAJC17 DnaJ (Hsp40) homolog, subfamily C, member 17 0.344 -0.237 1.18E-03 0.095 
KCNQ5 potassium channel, voltage gated KQT-like subfamily Q, member 
5 
0.343 0.334 1.30E-03 0.098 
NUDCD1 NudC domain containing 1 0.341 0.457 4.61E-04 0.065 
FAM226A family with sequence similarity 226, member A (non-protein 
coding) 
0.337 1.046 2.13E-04 0.052 
FAM226B family with sequence similarity 226, member B (non-protein 
coding) 
0.337 1.046 2.13E-04 0.052 
DDX49 DEAD (Asp-Glu-Ala-Asp) box polypeptide 49 0.330 0.199 5.12E-04 0.067 
PPIAL4D peptidylprolyl isomerase A (cyclophilin A)-like 4D 0.330 0.806 1.69E-04 0.052 
PPIAL4F peptidylprolyl isomerase A (cyclophilin A)-like 4F 0.330 0.806 1.69E-04 0.052 
PPIAL4E peptidylprolyl isomerase A (cyclophilin A)-like 4E 0.330 0.806 1.69E-04 0.052 
NDUFB7 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 7, 18kDa 0.330 -0.480 1.39E-03 0.099 
ZNF583 zinc finger protein 583 0.330 0.047 6.19E-04 0.070 
KLF16 Kruppel-like factor 16 0.328 -0.117 1.32E-03 0.098 
ZNF540 zinc finger protein 540 0.328 -0.347 1.01E-03 0.090 
CD83 CD83 molecule 0.325 -0.294 1.36E-03 0.099 
LOC727751 golgin A2 pseudogene 0.323 -0.112 8.80E-04 0.083 
ELAC1 elaC ribonuclease Z 1 0.320 -0.427 1.12E-03 0.093 
LOC100507639 uncharacterized LOC100507639 0.319 1.914 2.11E-05 0.021 
SFXN2 sideroflexin 2 0.319 -0.043 9.41E-04 0.087 
CCDC152 coiled-coil domain containing 152 0.318 -0.181 7.98E-04 0.077 
C5orf34 chromosome 5 open reading frame 34 0.317 -0.495 6.85E-04 0.071 
KIAA0895L KIAA0895-like 0.316 1.159 3.37E-05 0.024 
LINC01336 long intergenic non-protein coding RNA 1336 0.312 -0.300 5.43E-04 0.069 
ZFYVE9 zinc finger, FYVE domain containing 9 0.312 0.063 6.32E-04 0.070 
BLOC1S4 biogenesis of lysosomal organelles complex-1, subunit 4, 
cappuccino 
0.310 -0.154 9.20E-04 0.085 
PPIAL4C peptidylprolyl isomerase A (cyclophilin A)-like 4C 0.310 -0.254 3.48E-04 0.058 
MPDU1 mannose-P-dolichol utilization defect 1 0.310 0.372 7.86E-04 0.077 
DDX51 DEAD (Asp-Glu-Ala-Asp) box polypeptide 51 0.305 0.616 1.01E-04 0.045 
RBAK-
RBAKDN 
RBAK-RBAKDN readthrough 0.305 -0.369 3.36E-04 0.058 
DDX12P DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 12, pseudogene 0.301 -0.057 5.05E-04 0.067 
TUBA8 tubulin, alpha 8 0.299 -0.670 3.71E-04 0.059 
SSSCA1 Sjogren syndrome/scleroderma autoantigen 1 0.298 -0.540 4.39E-04 0.065 
UBE2E2 ubiquitin-conjugating enzyme E2E 2 0.297 -0.156 2.85E-04 0.052 
FAM223A family with sequence similarity 223, member A (non-protein 
coding) 
0.295 0.705 2.56E-04 0.052 
FAM223B family with sequence similarity 223, member B (non-protein 
coding) 
0.295 0.705 2.56E-04 0.052 
SNHG21 small nucleolar RNA host gene 21 0.293 -0.778 3.41E-04 0.058 
MUC20 mucin 20, cell surface associated 0.292 2.497 2.81E-07 0.001 
C2 complement component 2 0.290 1.360 2.34E-04 0.052 
ZNF256 zinc finger protein 256 0.288 -0.297 4.10E-04 0.062 
AMER1 APC membrane recruitment protein 1 0.287 0.778 3.47E-05 0.024 
C3orf35 chromosome 3 open reading frame 35 0.287 -0.566 4.03E-04 0.062 
LOC102723927 uncharacterized LOC102723927 0.286 1.720 1.58E-06 0.004 
SLC25A23 solute carrier family 25 (mitochondrial carrier; phosphate carrier), 
member 23 
0.284 0.342 1.39E-04 0.049 
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OR2T3 olfactory receptor, family 2, subfamily T, member 3 0.284 -0.812 2.87E-04 0.052 
RPS14P3 ribosomal protein S14 pseudogene 3 0.281 -0.270 1.50E-04 0.052 
MGC70870 C-terminal binding protein 2 pseudogene 0.281 -0.546 3.63E-04 0.059 
OVCH1 ovochymase 1 0.278 -0.523 9.04E-04 0.085 
SSSCA1-AS1 SSSCA1 antisense RNA 1 (head to head) 0.275 -0.223 2.32E-04 0.052 
SLC35F2 solute carrier family 35, member F2 0.270 -0.895 1.33E-04 0.049 
STX8 syntaxin 8 0.262 -0.512 1.99E-04 0.052 
PAX8-AS1 PAX8 antisense RNA 1 0.259 0.761 9.30E-06 0.010 
NLE1 notchless homolog 1 (Drosophila) 0.256 -0.062 5.76E-05 0.032 
ERBB2 erb-b2 receptor tyrosine kinase 2 0.245 -0.464 4.70E-05 0.029 
ACKR2 atypical chemokine receptor 2 0.219 0.256 2.36E-04 0.052 
YBEY ybeY metallopeptidase (putative) 0.217 -0.407 9.18E-05 0.043 
ALDOC aldolase C, fructose-bisphosphate 0.216 0.007 2.53E-05 0.023 
MIR4646 microRNA 4646 0.205 0.058 4.68E-06 0.006 
MTUS1 microtubule associated tumor suppressor 1 0.195 0.298 3.50E-06 0.005 
MUC12 mucin 12, cell surface associated 0.194 0.925 3.16E-07 0.001 
NDUFA6-AS1 NDUFA6 antisense RNA 1 (head to head) 0.184 1.098 6.65E-05 0.035 
ZNF382 zinc finger protein 382 0.177 -0.130 3.19E-06 0.005 
MIR8061 microRNA 8061 0.162 0.023 2.07E-06 0.004 
BTNL3 butyrophilin-like 3 0.161 1.818 1.88E-07 0.001 
C6orf10 chromosome 6 open reading frame 10 0.142 0.508 8.67E-08 0.001 
 
 
Supplemental Table 3: Target mRNAs of miRNA-340 shown to be significantly negative associated with 
maternal GDM in the screening group. Fold changes (FC) are shown in the 3rd and logarithmic counts per million 
(logCPM) are shown in the 4th column of the table. Unadjusted P-values and false discovery rates (FDR) of the paired analysis 
are indicated in the 5th and 6th column.  
Symbol Name FC logCPM P FDR 
GRB10 growth factor receptor-bound protein 10 0.549 1.748 7.93E-03 0.1486 
PAIP1 poly(A) binding protein interacting protein 1 0.509 0.726 4.33E-02 0.1973 
CRY2 cryptochrome circadian clock 2 0.559 1.904 1.22E-02 0.1614 
ID2 inhibitor of DNA binding 2, dominant negative helix-loop-helix protein 0.544 2.518 9.49E-03 0.1547 
PITPNB phosphatidylinositol transfer protein, beta 0.594 3.656 1.09E-02 0.1582 
SPRY3 sprouty homolog 3 (Drosophila) 0.644 2.767 2.50E-02 0.1789 
SCARB2 scavenger receptor class B, member 2 0.613 3.027 3.92E-02 0.1941 
 
 
Supplemental Table 4: mRNAs associated with maternal BMI within the screening population. Supplemental 
Table 4 shows mRNAs significantly (P<0.05, false discovery rate (FDR)<0.1) negative associated with maternal BMI. An 
unpaired analysis was conducted and adjusted for gestational diabetes, age, maternal weight gain, and pregnancy week. Fold 
changes (FC) are shown in the 3rd and logarithmic counts per million (logCPM), indicating the relative abundance of the 
transcript, are shown in the 4th column of the table. P-values and FDR as measures of significance of group differences are 
indicated in the 5th and 6th column. 
Symbol Name FC logCPM P FDR 
C6orf10 chromosome 6 open reading frame 10 0.760 0.521 1.11E-05 0.021 
NCR1 natural cytotoxicity triggering receptor 1 0.823 1.271 1.18E-06 0.003 
RMI2 RecQ mediated genome instability 2 0.842 -0.497 1.57E-04 0.083 
LOC727751 golgin A2 pseudogene 0.842 -0.069 9.65E-05 0.070 
CDKN1C cyclin-dependent kinase inhibitor 1C (p57. Kip2) 0.848 -0.321 1.16E-04 0.070 
UBE2E2 ubiquitin-conjugating enzyme E2E 2 0.849 -0.140 1.16E-04 0.070 
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RPH3A rabphilin 3A 0.858 3.037 1.55E-06 0.003 
HIST2H4B histone cluster 2. H4b 0.862 0.282 1.23E-04 0.070 
HIST2H4A histone cluster 2. H4a 0.862 0.282 1.23E-04 0.070 
QDPR quinoid dihydropteridine reductase 0.872 -0.405 2.00E-04 0.097 
NCAPG2 non-SMC condensin II complex. subunit G2 0.873 0.445 6.02E-05 0.067 
ZNF486 zinc finger protein 486 0.877 2.150 1.01E-04 0.070 
S100P S100 calcium binding protein P 0.877 1.854 6.12E-05 0.067 
DEFA1B defensin. alpha 1B 0.890 9.338 8.70E-05 0.070 
DEFA1 defensin. alpha 1 0.890 9.337 8.66E-05 0.070 
NOL12 nucleolar protein 12 1.083 2.110 6.96E-05 0.068 
PEX14 peroxisomal biogenesis factor 14 1.092 0.735 1.92E-04 0.097 
BTBD6 BTB (POZ) domain containing 6 1.093 1.727 2.09E-04 0.098 
PGAP3 post-GPI attachment to proteins 3 1.108 0.971 2.21E-05 0.037 
ITGB3 integrin. beta 3 (platelet glycoprotein IIIa. antigen CD61) 1.117 5.310 6.51E-05 0.067 
ZNF775 zinc finger protein 775 1.135 0.350 5.07E-05 0.068 
CCL3L1 chemokine (C-C motif) ligand 3-like 1 1.136 2.183 1.22E-08 0.001 
DDX11L10 DEAD/H (Asp-Glu-Ala-Asp/His) box helicase 11 like 10 1.142 1.913 1.27E-04 0.071 
CCL3L3 chemokine (C-C motif) ligand 3-like 3 1.150 2.052 1.27E-09 0.001 
SLC12A1 
solute carrier family 12 (sodium/potassium/chloride 
transporter). member 1 1.289 3.886 1.83E-07 0.001 
 
Supplemental Table 5: Plasma miRNAs negatively associated with maternal GDM. Supplemental Table 5 
shows miRNAs significantly (P<0.05, false discovery rate (FDR)<0.1) negative associated with maternal GDM in the plasma 
miRNA screening group. A multiple linear regression analysis (confounding covariates: BMI, gestational age, fetal sex, and 
maternal weight gain) miRNAs were sorted by fold change (FC), shown in the 2nd column of the table. Unadjusted and adjusted 
P-values are indicated in the 3rd and 4th column.  
Name FC P P adjusted 
 miR-95-3p 0.99 3.339E-03 2.292E+05 
 miR-3192-3p 0.97 7.258E-04 8.721E+04 
 miR-660-5p 0.96 2.254E-03 1.767E+05 
 miR-147b 0.95 8.219E-04 8.972E+04 
 miR-142-3p 0.95 5.939E-04 7.499E+04 
 miR-4497 0.94 6.636E-03 3.774E+05 
 let-7b-5p 0.93 2.854E+01 1.063E+03 
 miR-375 0.92 3.674E-05 8.508E+03 
 miR-125b-5p 0.91 3.769E-05 8.508E+03 
 miR-452-5p 0.91 1.112E-05 3.173E+03 
 miR-22-3p 0.90 6.563E-03 3.761E+05 
 miR-215-5p 0.89 5.228E-03 3.166E+05 
 miR-185-5p 0.87 7.685E-03 4.241E+05 
 miR-106b-3p 0.87 2.890E-03 2.132E+05 
 miR-1287-5p 0.86 4.720E-03 2.955E+05 
 miR-24-2-5p 0.86 5.332E-05 1.019E+04 
 miR-203a-3p 0.85 3.262E-03 2.292E+05 
 miR-203b-5p 0.85 3.262E-03 2.292E+05 
 miR-100-5p 0.85 3.592E-04 5.146E+04 
 miR-339-3p 0.84 8.917E-03 4.566E+05 
 miR-1250-5p 0.83 3.415E-03 2.292E+05 
 miR-182-5p 0.82 2.442E+01 9.576E+01 
 miR-25-3p 0.81 8.080E-05 1.433E+03 
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 miR-320e 0.81 3.371E-04 5.023E+04 
 miR-3615 0.81 1.136E-03 1.072E+05 
 miR-501-3p 0.81 1.593E-03 1.348E+04 
 miR-4665-5p 0.80 1.567E-03 1.342E+04 
 miR-576-3p 0.78 1.326E-03 1.162E+05 
 miR-1228-5p 0.76 3.073E-03 2.222E+05 
 miR-1307-3p 0.75 1.548E-03 1.341E+05 
 miR-320d 0.74 9.979E-04 1.006E+05 
 miR-16-2-3p 0.74 1.056E-03 1.035E+05 
 miR-6877-5p 0.74 3.530E-03 2.348E+05 
 miR-194-5p 0.72 5.751E-03 3.428E+05 
 miR-629-5p 0.72 7.524E-03 4.214E+05 
 miR-6820-3p 0.72 2.798E-03 2.106E+05 
 miR-320a 0.71 9.348E+01 3.028E+03 
 miR-23a-5p 0.70 2.659E-04 4.215E+04 
 miR-516b-5p 0.70 4.092E-03 2.628E+04 
 miR-17-3p 0.70 3.367E-05 8.360E+03 
 miR-193b-5p 0.70 7.587E-04 8.972E+04 
 miR-2110 0.69 3.766E-04 5.195E+04 
 miR-526b-5p 0.69 8.239E-03 4.436E+05 
 miR-629-3p 0.69 8.949E-03 4.566E+05 
 miR-486-3p 0.69 1.639E+00 1.221E+02 
 miR-486-5p 0.69 1.639E+00 1.221E+02 
 miR-512-3p 0.68 1.323E-03 1.162E+05 
 miR-1306-3p 0.67 3.070E-03 2.222E+05 
 miR-320c 0.67 9.817E-05 1.701E+04 
 miR-4504 0.66 8.794E-03 4.550E+05 
 miR-362-5p 0.66 6.884E-03 3.885E+04 
 miR-520c-5p 0.65 3.711E-03 2.425E+05 
 miR-320b 0.65 1.053E-05 3.137E+03 
 miR-518d-5p 0.64 3.406E-03 2.292E+05 
 miR-526a 0.64 3.406E-03 2.292E+05 
 miR-210-3p 0.64 8.307E-04 8.972E+04 
 miR-378a-3p 0.62 2.659E-03 2.036E+05 
 miR-3200-5p 0.62 8.335E-03 4.436E+05 
 miR-671-5p 0.61 7.230E-05 1.347E+04 
 miR-4429 0.61 4.296E-04 5.819E+04 
 miR-516a-5p 0.61 1.271E-03 1.162E+05 
 miR-193a-5p 0.60 9.939E-01 5.696E+02 
 miR-4516 0.57 9.342E-04 9.667E+04 
 miR-4320 0.56 8.710E-03 4.539E+05 
 miR-519a-5p 0.56 1.919E-01 3.233E+01 
 miR-522-5p 0.56 2.604E-01 3.233E+01 
 miR-518e-5p 0.56 2.349E-01 3.233E+01 
 miR-519b-5p 0.56 2.349E-01 3.233E+01 
 miR-519c-5p 0.56 2.349E-01 3.233E+01 
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 miR-523-5p 0.56 2.349E-01 3.233E+01 
 miR-183-5p 0.53 3.977E+01 1.411E+03 
 miR-520a-3p 0.53 2.066E+01 8.552E+02 
 miR-4508 0.52 7.848E-04 8.972E+04 
 miR-451b 0.51 6.188E-04 7.659E+04 
 miR-33b-5p 0.51 9.974E-03 4.794E+05 
 miR-378c 0.51 2.916E-04 4.526E+04 
 miR-144-5p 0.50 5.453E-04 7.127E+04 
 miR-483-5p 0.49 3.177E-04 4.831E+04 
 miR-378d 0.48 2.678E-03 2.036E+05 
 miR-4732-5p 0.46 1.249E-04 2.067E+04 
 miR-1180-3p 0.46 5.560E-04 7.142E+04 
 miR-4532 0.45 1.975E-03 1.653E+05 
 miR-4732-3p 0.39 3.490E-01 3.715E+01 
 miR-5001-3p 0.32 7.776E-03 4.260E+04 
 
Supplemental Table 6: Plasma miRNAs positively associated with maternal GDM. Supplemental Table 6 shows 
miRNAs significantly (P<0.05, false discovery rate (FDR)<0.1) positive associated with maternal GDM in the plasma miRNA 
screening group. A multiple linear regression analysis (confounding covariates: BMI, gestational age, fetal sex, and maternal 
weight gain) was conducted. miRNAs are sorted by fold change (FC), shown in the 2nd column of the table. Unadjusted and 
adjusted P-values are indicated in the 3rd and 4th column. 
Name FC P P adjusted  
 miR-503-5p 1.009 6.36E-03 3.70E-02 
 miR-7704 1.028 2.71E-05 6.96E-04 
 miR-6729-3p 1.032 2.23E-04 3.61E-03 
 miR-191-5p 1.036 1.11E-03 1.06E-02 
 miR-2355-3p 1.042 8.64E+01 2.93E-04 
 miR-4683 1.055 8.33E-03 4.44E-02 
 miR-129-5p 1.074 8.71E-03 4.54E-02 
 miR-425-3p 1.080 4.95E-03 3.07E-02 
 miR-6087 1.110 1.01E-03 1.01E-02 
 miR-28-5p 1.121 3.96E-05 8.67E-04 
 miR-296-3p 1.142 9.26E-04 9.67E-03 
 miR-3198 1.146 9.72E-03 4.70E-02 
 miR-3198 1.146 9.72E-03 4.70E-02 
 miR-206 1.151 3.76E-04 5.20E-03 
 miR-652-3p 1.193 3.79E-03 2.45E-02 
 miR-92a-3p 1.223 1.47E+01 7.32E-05 
 miR-3177-3p 1.234 9.31E-03 4.63E-02 
 miR-30d-5p 1.251 6.27E-04 7.66E-03 
 miR-221-3p 1.262 1.29E-03 1.16E-02 
 miR-92b-3p 1.268 1.68E+01 7.84E-05 
 miR-24-3p 1.287 9.20E-03 4.60E-02 
 miR-3074-5p 1.287 9.16E-03 4.60E-02 
 miR-150-5p 1.290 4.94E-04 6.57E-03 
 miR-10a-5p 1.313 1.11E+01 5.91E-05 
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 miR-199a-5p 1.321 9.69E-03 4.70E-02 
 let-7d-3p 1.343 8.17E-03 4.44E-02 
 miR-30b-5p 1.345 4.29E-03 2.71E-02 
 miR-128-3p 1.358 2.88E-03 2.13E-02 
 miR-584-5p 1.386 3.59E-04 5.15E-03 
 miR-625-3p 1.394 2.16E-03 1.73E-02 
 miR-625-5p 1.394 2.13E-03 1.72E-02 
 miR-128-3p 1.433 2.21E-03 1.75E-02 
 miR-654-3p 1.463 3.68E-03 2.43E-02 
 let-7c-5p 1.493 1.01E-05 3.13E-04 
 miR-10b-5p 1.520 6.13E-01 5.71E+01 
 miR-27b-3p 1.534 1.00E-03 1.01E-02 
 miR-30e-3p 1.587 2.46E-05 6.53E-04 
 miR-15b-3p 1.641 2.10E-03 1.72E-02 
 miR-493-5p 1.690 5.06E-03 3.09E-02 
 miR-766-3p 1.809 4.30E-05 8.90E-04 
 miR-23b-3p 1.826 8.35E-04 8.97E-03 
 miR-23a-3p 1.868 3.73E-05 8.51E-04 
 miR-361-5p 1.869 5.75E-03 3.43E-02 
 miR-199a-3p 1.870 8.42E-04 8.97E-03 
 miR-199b-3p 1.871 8.43E-04 8.97E-03 
 miR-224-5p 1.892 6.48E-03 3.74E-02 
 let-7f-5p 2.090 5.81E-03 3.43E-02 
 miR-223-3p 2.104 4.93E-05 9.88E-04 
 miR-331-3p 2.157 2.11E-03 1.72E-02 
 miR-628-3p 2.313 8.49E-03 4.49E-02 
 miR-574-3p 2.345 2.45E-03 1.90E-02 
 miR-4523 2.581 7.61E-05 1.38E-03 
 
Supplemental Table 7: Primer sequences of qPCR experiments   
Gene  Forward primer (5’→3’) Reverse primer (5’→3’) 
APL ATAAGGGACCCATGCCTTTC CCTCCAGAGAAGCAGACCAA 
APJ CATCTTCGTCAACATGTACGC GGTAGCGGTCGAAGCTGA 
CRY2 CAAGTCCTTCAGTGGGGA AC CAAGTCCTTCAGTGGGGAAC 
FABP3 AGCAGATGACAGGAAGGTCAA CAATTAGCTCCCGCACAAGT 
FABP4 CCTTTAAAAATACTGAGATTTCCTTCA GGACACCCCCATCTAAGGTT 
FAT TGCCTATTCTTTGGCTTAATGAG TTACTTGACTTCTGAACATGTTTGC 
GRB10 TTCTGGTAAAGGAGC ATTCCA AGGACGAGCAAACCAGGAC 
ID2 CTGGACTCGC ATCCCACTAT  TAACTCAGAAGGGAATTCAGAAGC 
IL1B CTGTCCTGCGTGTTGAAAGA TTGGGTAATTTTTGGGATCTACA 
IL6 CAGGAGCCCAGCTATGAACT GAAGGCAGCAGGCAACAC 
IL8 AGACAGCAGAGCACACAAGC AGGAAGGCTGCCAAGAGAG 
LIPG ATTGCCAGGATGCTCGACT  GTGGACATTCCCGAGAGAAA 
LPL AGGAGCATTACCCAGTGTCC CCAAGGCTGTATCCCAAGAG 
PAIP1 AATCC TCACAACCATCCTCATAG GAACTCGGAGTCAGCAATGG 
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PITPNB CGAGACTCAGAAAGAACTAGAAACA TGACCCTACAGGGGACTCAT 
PLIN2 CGTTGCAGTTGATCCACAA GGATACTGGTCCTTTGTACTGAGAT 
RPS13 CCCCACTTGGTTGAAGTTGA ACACCATGTGAATCTCTCAGGA 
RPS13 CCCCACTTGGTTGAAGTTGA ACACCATGTGAATCTCTCAGGA 
SCARB GGCCGATGCTGCTTCTAC CAAATGCCTCAGTACCATTCC 
SLC27A1 GTCGTCCTCCGCAAGAAAT TCCCCGATGTACTGAACCAC 
SLC27A4 TGCCTGAGCTGCACAAAA AGAACAGCGGGTCTTTCACA 
SPRY3 AAATCATCTGTTAGCCCCTAACTC- TCATATGAAATGTATCAA GGAACCA 
TLR2 CTCTCGGTGTCGGAATGTC  AGGATCAGCAGGAACAGAGC  
TLR4 AGCCATGGCCTTCCTCTC TTCAGCTCCATGCATTGATAA 
TNF-α CAGCCTCTTCTCCTTCCTGAT GCCAGAGGGCTGATTAGAGA 
   
miRNA gene  Primer sequence 
RNU6B  Not published 
let-7g-5p  UGAGGUAGUAGUUUGUACAGUU 
miRNA-142-5p  CAUAAAGUAGAAAGCACUACU 
miRNA-143-3p  UGAGAUGAAGCACUGUAGCUC 
miRNA-19a-3p  UGUGCAAAUCUAUGCAAAACUGA 
miRNA-19b-3p  UGUGCAAAUCCAUGCAAAACUGA 
miRNA-340-5p  UCCGUCUCAGUUACUUUAUAGC 
 
 
 
 
 
 
 
 
 
 
 
 
